

**UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF KENTUCKY
DIVISION**

ANGELA HALL

Plaintiff,

VS.

NOVO NORDISK A/S,
NOVO NORDISK
NORTH AMERICA OPERATIONS A/S,
NOVO NORDISK US HOLDINGS INC.,
NOVO NORDISK US COMMERCIAL
HOLDINGS INC.,
NOVO NORDISK INC.,
NOVO NORDISK RESEARCH CENTER
SEATTLE INC.,
NOVO HOLDINGS A/S,
NOVO HOLDINGS EQUITY US INC.,
NOVO VENTURES US, INC., and
NOVO NORDISK PHARMACEUTICAL
INDUSTRIES LP,

Defendants.

Case No.

COMPLAINT AND JURY TRIAL DEMAND

COMPLAINT AND DEMAND FOR A JURY TRIAL

Plaintiff Angela Hall by and through her attorneys, files this Complaint against Defendants Novo Nordisk A/S, et. al. for their failure to warn Plaintiff about the true risks of their weight loss drugs, Wegovy and Ozempic, as well as for negligence and deceptive and unfair marketing of the same. This is an action for damages suffered by Angela Hall who was severely injured as a result Defendants' widespread marketing of their drugs, Wegovy and Ozempic, and her subsequent use of Wegovy, an injectable prescription medication that is approved for weight loss. In support

thereof, Plaintiff alleges as follows:

PARTIES

1. Plaintiff Angela Hall is a citizen and resident of Catlettsburg, Boyd County, in the Commonwealth of Kentucky.

2. Defendant Novo Nordisk Inc. (“Novo Nordisk”) is a Delaware corporation that has its principal place of business at 800 Scudders Mill Road, Plainsboro, New Jersey 08536. Novo Nordisk has transacted and conducted business and derived substantial revenue from within the Commonwealth of Kentucky that relates to the allegations in this Complaint.

3. Defendant Novo Nordisk Inc. is wholly owned by Defendant Novo Nordisk US Commercial Holdings, Inc.

4. Defendant Novo Nordisk US Commercial Holdings Inc. is a Delaware corporation with its principal place of business at 103 Foulk Road, Wilmington, Delaware 19803.

5. Defendant Novo Nordisk US Commercial Holdings Inc. is wholly owned by Defendant Novo Nordisk US Holdings Inc.

6. Defendant Novo Nordisk US Holdings Inc. is a Delaware corporation with its principal place of business at 103 Foulk Road, Wilmington, Delaware 19803.

7. Defendant Novo Nordisk US Holdings Inc. is wholly owned by Defendant Novo Nordisk A/S.

8. Defendant Novo Nordisk A/S is a public limited liability company organized under the laws of Denmark with its principal place of business in Bagsværd, Denmark.

9. Defendant Novo Nordisk North America Operations A/S is a company organized under the laws of Denmark with its principal place of business in Bagsværd, Denmark.

10. Novo Nordisk Research Center Seattle, Inc. is a Delaware corporation with its principal place of business at 530 Fairview Ave. N., Seattle, Washington.

11. Novo Nordisk Pharmaceutical Industries LP is a Delaware partnership with its principal place of business at 3611-3612 Powhatan Road, Clayton, North Carolina.

12. Novo Holdings A/S is a company organized under the laws of Denmark with its principal place of business in Hellerup, Denmark.

13. Novo Holdings Equity US Inc. is a Delaware corporation with its principal place of business at 200 Clarendon Street Floor 45 Boston, MA 02142 USA.

14. Novo Ventures (US) Inc. is a Massachusetts corporation with its principal place of business at 501 2nd Street Suite 300 San Francisco, CA 94107.

15. Defendant Novo Nordisk A/S and its subsidiaries and affiliates named herein are collectively referenced as “the Novo Nordisk Defendants” and “Novo Nordisk.”

16. The Novo Nordisk Defendants transacted and conducted business in the Commonwealth of Kentucky that relates to the allegations in this Complaint.

17. The Novo Nordisk Defendants derived substantial revenue from goods and products sold and used in the Commonwealth of Kentucky.

18. The Novo Nordisk Defendants expected or should have expected their acts to have consequences within the Commonwealth of Kentucky, and derived substantial revenue from interstate commerce.

19. Upon information and belief, Defendants purposefully availed themselves of the privilege of conducting business and activities within the Commonwealth of Kentucky, thus invoking the benefits and protections of its laws.

20. The Novo Nordisk Defendants' website states that "the vast majority of our U.S. injectable diabetes and obesity products are produced and packaged at the Clayton aseptic fill-finish site."¹ Upon information and belief, this refers to Novo Nordisk's manufacturing facility in Clayton, North Carolina, operated by Novo Nordisk Pharmaceutical Industries LP.

21. Upon information and belief, Defendant Novo Nordisk Pharmaceutical Industries LP is the labeler for Ozempic and Wegovy, and Defendants Novo Nordisk A/S and Novo Nordisk Inc. are identified on Ozempic and Wegovy's label.² The Novo Nordisk Defendants also designed, researched, manufactured, tested, advertised, promoted, marketed, sold, and/or distributed Ozempic and Wegovy.

22. Upon information and belief, Defendants failed to warn the end users of Ozempic and Wegovy of the complications and devastating effects of which the company knew or should have known.

23. Upon information and belief, Defendants' marketing was deceptive and misleading about the true risks associated with use of Ozempic and Wegovy of which the company knew or should have known.

JURISDICTION AND VENUE

24. This Court has subject matter jurisdiction under 28 U.S.C. §1332(a) as the matter in controversy exceeds the value of \$75,000, exclusive of interest and costs and is between citizens of different states and/or a foreign state, as Plaintiff is a citizen of the Commonwealth of Kentucky and each Defendant is neither incorporated nor has its principal place of business in the Commonwealth of Kentucky.

¹ <https://www.novonordisk-us.com/about/who-we-are/north-carolina.html> (last visited April 13, 2024).

² <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79> (last visited April 13, 2024).

25. This Court has personal jurisdiction over Defendants consistent with the United States Constitution and Kentucky Statute § 454.210 (Kentucky’s “long arm” statute), as Plaintiff’s claims arise out of Defendants’ transaction of business and tortious acts in this Commonwealth, their supply of goods in this Commonwealth, their causing of tortious injury by an act or omission within this Commonwealth, their causing of tortious injury in this Commonwealth given their regular business and persistent course of conduct in this Commonwealth from which they derive substantial revenue from goods used or consumed and services rendered in this judicial district, their doing a series of similar acts for the purpose of thereby realizing pecuniary benefit, and by virtue of Defendants’ substantial, continuous, and systematic contacts with the Commonwealth of Kentucky. The Plaintiff was exposed to Wegovy in this judicial district.

26. Venue is proper under 28 U.S.C. § 1391(b)(2) as a substantial part of the events or omissions giving rise to the claim occurred in this District. Defendants routinely market their products at issue in this District and conduct business in this District related to their products at issue in the Commonwealth of Kentucky.

BACKGROUND

I. An Accidental Blockbuster: The Development of Ozempic and Wegovy

27. In the early 1990s, Novo Nordisk researchers discovered that when they injected into rats a chemical compound known as liraglutide—a GLP-1 (glucagon-like peptide-1) agonist—the drug caused the rats to stop eating almost entirely.³

28. GLP-1 agonists are a class of medications that can help lower blood sugar levels and promote weight loss.⁴ An agonist is a manufactured substance that attaches to a cell receptor

³ <https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html> (last visited April 12, 2024)

⁴ <https://my.clevelandclinic.org/health/articles/13901-glp-1-agonists> (last visited April 12, 2024)

and causes the same action as the naturally occurring substance.⁵ Thus, GLP-1 agonists work by mimicking a naturally occurring GLP-1 hormone.

29. To describe the process in other words, GLP-1 medications bind to GLP receptors to trigger the effects (or roles) of the GLP-1 hormone. The higher the dose of the GLP-1 agonist, the more extreme the effects.⁶

30. “These rats, they starved themselves,” said one Novo Nordisk scientist, Lotte Bjerre Knudsen, in a video series released by the Novo Nordisk Foundation, “so we kind of knew there was something in some of these peptides that was really important for appetite regulation.”⁷

31. Later testing in human subjects revealed that those who received an intravenous drip of GLP-1 agonist ate 12% less at a lunch buffet than those who got a placebo.⁸

32. Consequently, Novo Nordisk decided to study liraglutide as not only a diabetes drug which had been shown to lower blood sugars, but also as a drug to treat obesity.⁹

33. Years later, in 2010, liraglutide was approved for the treatment of diabetes by the FDA under Novo Nordisk's brand name Victoza,¹⁰ at which point Novo Nordisk moved forward with studying the drug for weight loss.¹¹

34. After clinical trials, in 2014 the FDA approved liraglutide for treatment of obesity under Novo Nordisk's brand name Saxenda as a daily injectable.¹²

⁵ *Id.*

⁶ *Id.*

⁷ <https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html> (last visited April 12, 2024).

⁸ *Id.*

⁹ *Id.*

¹⁰ [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957743/#:~:text=The%20incretin%20mimetic%20liraglutide%20\(Victoza,adults%20with%20type%2D2%20diabetes.&text=Liraglutide%20is%20also%20approved%20in%20Europe%20and%20Japan](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957743/#:~:text=The%20incretin%20mimetic%20liraglutide%20(Victoza,adults%20with%20type%2D2%20diabetes.&text=Liraglutide%20is%20also%20approved%20in%20Europe%20and%20Japan) (last visited April 12, 2024).

¹¹ <https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html> (last visited April 12, 2024).

¹² *Id.*

35. Saxenda's effects on weight loss, however, were modest; patients lost about 5% of their weight.¹³

36. In an effort to find ways to make a longer-lasting GLP-1 agonist so patients would not have to inject themselves every day, Novo Nordisk created a new molecule with the chemical name semaglutide.¹⁴

37. Novo Nordisk branded semaglutide as Ozempic, and on December 5, 2016, the Novo Nordisk Defendants announced submission of Ozempic's new drug application (NDA) to the FDA for regulatory approval of once-weekly injectable in 0.5 mg or 1 mg for treatment of Type 2 diabetes. In the announcement, Defendants represented that in clinical trials "once-weekly" Ozempic had a safe and well-tolerated profile, and Defendants represented that the most common adverse event was nausea.¹⁵

38. On December 5, 2017, the FDA approved the application and granted premarket approval as NDA 209637.¹⁶

39. In addition to diabetic control, Ozempic also caused 15% weight loss, which was three times the loss caused by its predecessor, Saxenda.¹⁷

40. Just one year after Ozempic's approval for diabetes, Defendants started a clinical trial in patients who were overweight or suffered from obesity.¹⁸

¹³ *Id.*

¹⁴ *Id.*

¹⁵ <https://ml.globenewswire.com/Resource/Download/d2f719e1-d69f-4918-ae7e-48fc6b731183> (last visited April 12, 2024).

¹⁶ https://www.accessdata.fda.gov/Ozempicatfda_docs/appletter/2017/209637s000ltr.pdf (last visited April 12, 2024).

¹⁷ <https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html> (last visited April 12, 2024).

¹⁸ *Id.*

41. The results of the trial demonstrated that for participants who were overweight or obese, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.¹⁹

42. Importantly, the trial data also pointed out that more participants in the semaglutide group than in the placebo group discontinued treatment owing to gastrointestinal events (59 [4.5%] vs. 5 [0.8%]).

43. By March of 2021, Defendants had completed the clinical trial studying semaglutide for weight loss, and its results were published March 18, 2021.²⁰

44. In addition to the results, the published study, which was funded by Defendants, argued: “Obesity is a chronic disease and global public health challenge.”²¹

45. On March 20, 2019, Defendant Novo Nordisk Inc. submitted a supplemental new drug application for Ozempic 0.5 mg or 1 mg injection, requesting approval to expand its marketing of Ozempic by adding an indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.²² On January 16, 2020, the FDA approved this new indication.²³

46. Then, on May 28, 2021, Defendant Novo Nordisk Inc. submitted another sNDA requesting approval for a higher 2 mg dose of Ozempic injection. On March 28, 2022, the FDA approved this request.²⁴

¹⁹ <https://www.nejm.org/doi/full/10.1056/NEJMoa2032183> (last visited April 12, 2024)

²⁰ <https://www.nejm.org/doi/full/10.1056/NEJMoa2032183> (last visited April 12, 2024)

²¹ *Id.*

²² <https://www.prnewswire.com/news-releases/novo-nordisk-files-for-us-fda-approval-of-oral-semaglutide-for-blood-sugar-control-and-cardiovascular-risk-reduction-in-adults-with-type-2-diabetes-300815668.html> (last visited on April 12, 2024).

²³ https://www.accessdata.fda.gov/Ozempicatfda_docs/applletter/2020/209637Orig1s003ltr.pdf (last visited April 12, 2024).

²⁴ https://www.accessdata.fda.gov/Ozempicatfda_docs/applletter/2022/209637Orig1s009ltr.pdf (last visited April 12, 2024).

47. In their press release, Defendants represented Ozempic as having “proven safety and efficacy” and they continued to advertise that “it can help many patients lose some weight.”²⁵ As with its prior press releases, Defendants disclosed Important Safety Information and provided link to the Medication Guide and Prescribing Information. However, severe gastrointestinal events, including gastroparesis and gastroenteritis, were not identified as risks.

48. On June 4, 2021, the FDA announced that Wegovy was approved for use in adults with obesity (BMI over 30) or overweight (BMI over 27) and at least one chronic health condition,²⁶ and was the first FDA approved drug for weight loss since 2014.²⁷

49. Wegovy and Ozempic are chemically identical and primarily differ based upon dosage.

50. On December 23, 2022, Novo Nordisk announced FDA approval of Wegovy injection, along with reduced calorie meal plan and exercise, for the treatment of obesity in adolescents aged 12 years and older.²⁸

II. Defendants Create a Market: Millions Spent on Marketing and Promotion Create a Media Frenzy and Mega Seller

51. Since Defendants discovered GLP-1 agonists’ potential use for weight loss, Defendants began working to change medical consensus as it relates to obesity.

52. Conventionally, evidence-based approaches to obesity focused on lifestyle: eating whole, nutritious foods, exercising, reducing stress, and obtaining adequate sleep. In contrast,

²⁵ <https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-of-higher-dose-ozempic-2-mg-providing-increased-glycemic-control-for-adults-with-type-2-diabetes-301512209.html> (last visited April 12, 2024).

²⁶ <https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014> (last accessed April 12, 2024)

²⁷ *Id.*

²⁸ <https://www.novonordisk-us.com/media/news-archive/news-details.html?id=151389> (last visited April 12, 2024).

Defendants have spent millions of dollars marketing the belief that sustained weight loss is only achievable by using Defendants' medications at a cost of more than \$1000 per month.

53. Throughout their marketing, Defendants fail to disclose the true serious side effects of Ozempic and Wegovy, including but not limited to hospitalization and death.

54. Defendants also fail to disclose in their label and patient brochure for Ozempic and/or Wegovy that in order to maintain any weight loss, the patient must stay on the drug permanently or most patients will regain most of the weight within one year and virtually all the weight will be regained within five years.²⁹

55. When the Novo Nordisk Defendants announced that they had started selling Ozempic in the United States, they touted the medication as a “new treatment option[]” that “addresses the concerns and needs of people with diabetes[.]” The Novo Nordisk Defendants offered an “Instant Savings Card to reduce co-pays to as low as \$25 per prescription fill for up to two years.”

56. Indeed, some patients will regain even more weight after stopping the drug, so that they end up heavier than before starting Ozempic and/or Wegovy.³⁰ This is also not disclosed in the label or patient brochure.

57. Novo Nordisk was not permitted to market Ozempic for weight loss without FDA approval for that specific indication,³¹ but before Wegovy ever received separate approval for treatment of weight loss, Novo Nordisk had already begun mentioning weight loss in their Ozempic commercials.³²

²⁹ <https://www.cnn.com/2023/03/29/people-taking-obesity-drugs-ozempic-and-wegovy-gain-weight-once-they-stop-medication.html>; <https://pubmed.ncbi.nlm.nih.gov/35441470/>

³⁰ <https://www.cnn.com/2023/03/29/people-taking-obesity-drugs-ozempic-and-wegovy-gain-weight-once-they-stop-medication.html> (last visited April 12, 2024)

³¹ <https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html> (last visited April 12, 2024).

³² *Id.*

58. On July 30, 2018, the Novo Nordisk Defendants launched their first television ad for Ozempic to the tune of the 1970s hit pop song “Magic” by Pilot, wherein the Novo Nordisk Defendants advertised that “adults lost on average up to 14 pounds” when taking Ozempic.³³



59. Over the next five years, the Novo Nordisk Defendants spent \$884,000,000 on running television ads in the United States to promote its semaglutide drugs (Ozempic, Wegovy, and another of its lesser known GLP-1 agonists, Rybelsus) with most advertisements allocated towards Ozempic.³⁴

60. By 2021, Defendants’ aggressive marketing of the weight loss benefits of Ozempic, sophisticated use of social media, and America’s socially ingrained desire to be thin had reached a tipping point.³⁵

61. Defendants’ aggressive marketing includes a number of different platforms,

³³ <https://www.ispot.tv/ad/d6Xz/ozempic-oh> (last visited April 13, 2024).

³⁴ https://medwatch.com/News/Pharma_Biotech/article15680727.ece (last visited April 12, 2024).

³⁵ <https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html> (last visited April 12, 2024).

including over 4,000 marketing advertisements for Ozempic and similar weight-loss medications, including Wegovy, that have been placed on Facebook and Instagram.³⁶

62. According to open payments data, Novo Nordisk spent over \$33,000,000.00 on marketing/consulting/travel/food and beverage/etc. to physicians in 2022 alone.³⁷

63. For its two drugs approved specifically for obesity, Wegovy and Saxenda, Novo Nordisk has spent at least \$25.8 million over the past decade to U.S. medical professionals to promote sales of the drug.³⁸

64. Overall, at least 57 U.S. physicians each accepted at least \$100,000 from Novo in payments associated with Wegovy or Saxenda over the past decade. A Reuters special report found these physicians were an influential group: Forty-one were obesity specialists who run weight-management clinics, work at academic hospitals, write obesity-treatment guidelines, or hold top positions at medical societies.³⁹

65. Dr. Donna Ryan, a Louisiana researcher and former president of The Obesity Society, has accepted more than \$1 million from Novo over the last decade, including \$600,691 related to Wegovy and Saxenda, the analysis found.⁴⁰ As reported in Reuters, Ryan was instrumental in persuading the U.S. Office of Personnel Management to cover Wegovy and similar drugs for millions of federal workers.⁴¹

66. On TikTok, the hashtag #Ozempic had 273 million views as of November 22, 2022.⁴²

³⁶ <https://www.nbcnews.com/tech/internet/ozempic-weight-loss-drug-ads-instagram-wegovy-semaglutide-rcna88602> (last visited April 12, 2024).

³⁷ <https://openpaymentsdata.cms.gov/company/100000000144> (last visited April 12, 2024).

³⁸ <https://www.reuters.com/investigates/special-report/health-obesity-novonordisk-doctors/> (last visited April 12, 2024)

³⁹ *Id.*

⁴⁰ *Id.*

⁴¹ *Id.*

⁴² <https://www.nytimes.com/2022/11/22/well/ozempic-diabetes-weight-loss.html> (last visited April 12, 2024).

67. The hashtag #wegovyweightloss had 163.2 million views as of September 9, 2023, on TikTok.

68. The hashtag #ozempicjourney had 199.5 million views, as of September 9, 2023, on TikTok.

69. Novo Nordisk partnered directly with Meta and Instagram to run marketing campaigns. One diabetes marketing campaign achieved a dramatic 28% direct engagement rate with their polls.⁴³ This was a lauded result presented in a case study by Meta.

70. On July 10, 2023, a global media company declared Ozempic as “2023’s buzziest drug” and one of the “Hottest Brands, disrupting U.S. culture and industry.”⁴⁴

71. Novo Nordisk reportedly spent approximately one hundred million dollars advertising Ozempic in 2022.⁴⁵ Ozempic ranked as the sixth most advertised prescription drug brand in 2022, with a U.S. measured media spend of \$181 million, according to Vivvix spending data and Pathmatics paid social data as reported in Ad Age Leading National Advertisers 2023.⁴⁶

72. In 2023, over \$491 million was spent advertising “diabesity” drugs, including Ozempic and Wegovy.⁴⁷

73. Jimmy Kimmel joked about Ozempic at the Oscars.⁴⁸

74. Howard Stern has joked and discussed Ozempic.⁴⁹ Interestingly, Stern notes that the “catchy” theme song “distracts” the listener from actually hearing any of the listed side

⁴³ <https://business.instagram.com/success/novo-nordisk> (last visited Sept. 17, 2023).

⁴⁴ <https://adage.com/article/special-report-hottest-brands/ozempic-hottest-brands-most-popular-marketing-2023/2500571> (last visited on April 12, 2024).

⁴⁵ <https://www.newyorker.com/magazine/2023/03/27/will-the-ozempic-era-change-how-we-think-about-being-fat-and-being-thin> (last visited April 12, 2024).

⁴⁶ https://adage.com/article/special-report-hottest-brands/ozempic-hottest-brands-most-popular-marketing-2023/2500571?utm_source=exchange&utm_medium=email&utm_campaign=t5687390 (last visited April 12, 2024).

⁴⁷ <https://www.mmm-online.com/home/channel/spending-on-ozempic-wegovy-surges/> (last visited April 12, 2024).

⁴⁸ <https://www.usatoday.com/story/life/health-wellness/2023/03/13/ozempic-sweeping-hollywood-celebrities-weight-loss/11428801002/> (last visited April 12, 2024).

⁴⁹ <https://www.youtube.com/watch?v=QD-nCQn1Ads> (last visited April 12, 2024).

effects.⁵⁰

75. Both Elon Musk and Chelsea Handler are among the celebrities who have admitted to using the drug for weight loss.⁵¹

76. Novo Nordisk has partnered directly with other celebrities as paid spokespersons, including Queen Latifah.⁵²

77. As part of overall campaigns to target Black, Brown, and Hispanic consumers with their marketing campaigns and social media partnerships with influencers, in addition to Queen Latifah Novo Nordisk has compensated Yvette Nicole Brown to serve as a paid spokesperson.⁵³

78. In 2021, Novo Nordisk even gave between \$100,000 and \$399,999 to the Congressional Black Caucus Foundation.⁵⁴

79. Novo Nordisk combined with Eli Lilly are spending roughly ten million dollars annually on lobbying.⁵⁵

80. A primary focus of that lobbying is the proposed Treat and Reduce Obesity Act, which has been introduced in congressional sessions annually since 2012. The Treat and Reduce Obesity Act would require Medicare to cover, among other treatments, chronic-weight-management drugs.⁵⁶

81. Defendants and their competitors have promoted the message that “obesity is a

⁵⁰ *Id.*

⁵¹ <https://www.insider.com/ozempic-celebrities-denied-semaglutide-wegovy-weight-loss-drugs-khloe-kardashian-2023-3#chelsea-handler-said-she-was-on-semaglutide-without-realizing-it-7> (last visited April 12, 2024).

⁵² <https://www.npr.org/sections/health-shots/2023/08/07/1192279278/ozempic-and-wegovy-maker-courts-prominent-black-leaders-to-get-medicare-favor> (last visited April 12, 2024)

⁵³ <https://www.essence.com/health-and-wellness/yvette-nicole-brown-fighting-obesity/> (last visited April 12, 2024); <https://www.itsbiggerthan.com/series/> (last visited April 12, 2024)

⁵⁴ <https://www.npr.org/sections/health-shots/2023/08/07/1192279278/ozempic-and-wegovy-maker-courts-prominent-black-leaders-to-get-medicare-favor> (last visited April 12, 2024)

⁵⁵ <https://www.newyorker.com/magazine/2023/03/27/will-the-ozempic-era-change-how-we-think-about-being-fat-and-being-thin> (last visited April 12, 2024)

⁵⁶ *Id.*; <https://www.fiercepharma.com/pharma/novo-nordisk-eli-lilly-and-boehringer-get-behind-lawmakers-bill-enable-obesity-drug-coverage> (last visited April 12, 2024)

disease” and largely due to “genetics” and “not a choice,” in addition to promoting the message that coverage of pharmaceutical drugs for obesity is a step toward health equity.⁵⁷ What is not promoted is that this message directly impacts Defendants’ pocketbooks by encouraging insurance to cover their drugs. Defendants’ messaging encourages patients and prescribers to forgo lifestyle changes – long the cornerstone of healthy weight loss – in favor of powerful, dangerous, and expensive drugs.

82. Anticipating the passage of this bill within the next few years, Morgan Stanley forecasts that U.S. revenue from such drugs will increase four-hundredfold by the end of the decade. Obesity looks “set to become the next blockbuster pharma category,” it declared in a report last year, which also predicted that social media and word of mouth will create an “exponential virtuous cycle” around the new medications: a quarter of people with obesity will seek treatment from physicians, up from the current seven per cent, and more than half of those who do will begin taking medicine.⁵⁸

83. Defendants also own and operate several marketing campaign websites that are created for the purposes of educating on the science of obesity and creating a change in how obesity is understood and treated.

84. This includes the website “The Truth about Weight.”⁵⁹

85. This website includes headings such as “my weight, my culture” with an apparent focus to target Black, Brown, and Hispanic individuals.⁶⁰

⁵⁷ <https://www.statnews.com/2022/01/06/recognizing-obesity-as-a-disease-is-a-step-toward-health-equity/> (last visited April 12, 2024); <https://www.womenshealthmag.com/health/a42679413/causes-of-obesity-genetics-lifestyle/> (last visited April 12, 2024)

⁵⁸ <https://www.newyorker.com/magazine/2023/03/27/will-the-ozempic-era-change-how-we-think-about-being-fat-and-being-thin> (last visited April 12, 2024).

⁵⁹ <https://www.truthaboutweight.com/> (last visited April 12, 2024).

⁶⁰ <https://www.truthaboutweight.com/understanding-excess-weight/my-weight-my-culture.html> (last visited April 12, 2024).

86. Defendants also own and operate the website “It’s Bigger Than Me.”⁶¹ This advertising campaign website promotes the message that obesity is a chronic health condition that requires pharmaceutical drugs to manage.⁶²

87. The hashtag #itsbiggerthan also reveals paid social media influencers promoting “body positivity” and linking back to Novo Nordisk’s website (and ultimately to their weight loss drugs).

88. Novo Nordisk’s presentation on capital markets day makes it clear that these campaigns are designed to activate more people to seek treatment for obesity.⁶³

89. Defendants have also spent significant resources aligning themselves and infiltrating their influence into physician and advocacy groups.

90. This includes the American Board of Obesity Medicine. The former Director of the American Board of Obesity Medicine who served from 2017 to November of 2021 received payments by Novo Nordisk during her time as director of the American Board of Obesity Medicine.⁶⁴

91. This former director of the American Board of Obesity Medicine currently promotes their GLP-1 agonists for weight loss as part of their telehealth company and continues to receive payments.⁶⁵

92. At least one member of the American Board of Obesity Medicine that helped write

⁶¹ <https://www.itsbiggerthan.com> (last visited April 12, 2024).

⁶² *Id.*

⁶³ <https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/capital-markets-day-2022/P5-obesity-care.pdf> (last visited April 12, 2024).

⁶⁴ <https://joinfound.com/pages/medication-biology> (last visited April 12, 2024); <https://openpaymentsdata.cms.gov/physician/1294300> (last visited April 12, 2024); <https://www.linkedin.com/in/rekha-kumar-m-d-m-s-70b481237/> (last visited April 12, 2024).

⁶⁵ <https://joinfound.com/pages/medication-biology> (last visited April 12, 2024); <https://openpaymentsdata.cms.gov/physician/1294300> (last visited April 12, 2024); <https://www.linkedin.com/in/rekha-kumar-m-d-m-s-70b481237/> (last visited April 12, 2024).

the guidelines for obesity management has received payments directly from Novo Nordisk according to Open Payments Data during the same time he wrote those guidelines.⁶⁶

93. Dr. Jamy Ard of Wake Forest University is the incoming president of The Obesity Society. In that role, he will oversee the group's effort to write new "standards of care," which primary-care doctors often use as a quick-reference guide, with advice on Wegovy and similar therapies.⁶⁷ Dr. Ard has accepted more than \$200,000 from Novo Nordisk, according to Reuters.⁶⁸

94. Novo Nordisk contributes money directly to education courses used to satisfy continuing education requirements or to prepare for certification in obesity medicine. This includes contributing \$10,000 to Dr. Kaplan – a physician who has received over \$1 million dollars from Novo Nordisk over the past decade – popular education course on obesity treatment.⁶⁹

95. Novo Nordisk has also influenced and infiltrated the public health partners of the American Board of Obesity Medicine.

96. The American Board of Obesity Medicine lists public health "partners" on their website.⁷⁰

97. Novo Nordisk serves on the board and/or provides direct financial contributions to many of these public health advocacy groups.

98. This includes Obesity in Action Coalition, to which Novo Nordisk contributes more than \$100,000 annually.⁷¹ Novo Nordisk has been a partner since 2013, before any of its drugs were approved for weight loss.

99. Novo Nordisk also serves on the Corporate Council of American Society for

⁶⁶<https://openpaymentsdata.cms.gov/physician/1379381> (last visited April 12, 2024); see also <https://www.abom.org/karl-nadolsky/>.

⁶⁷ <https://www.reuters.com/investigates/special-report/health-obesity-novonordisk-doctors/>

⁶⁸ <https://www.reuters.com/investigates/special-report/health-obesity-novonordisk-doctors/>

⁶⁹ <https://www.reuters.com/investigates/special-report/health-obesity-novonordisk-doctors/>

⁷⁰ <https://www.abom.org/> (last visited April 12, 2024).

⁷¹ <https://www.obesityaction.org/corporate-partners/> (last visited April 12, 2024).

Metabolic and Bariatric Society, another public health partner of the American Board of Obesity Medicine.⁷²

100. Novo Nordisk is also a corporate member and directly financially contributes to Stop Obesity Alliance, yet another public health partner of the American Board of Obesity Medicine.⁷³

101. Novo Nordisk is a member of additional advocacy organizations and lobbying groups separate and apart from these public health partners of the American Board of Obesity Medicine.

102. This includes the Obesity Care Advocacy Network, which lobbies for legislation to expand access to Novo Nordisk's drugs.⁷⁴

103. In addition to promoting lobbying groups, Novo Nordisk has "paid more than \$250,000 in campaign contributions to members of Congress in an effort to pass legislation to make the U.S. government pay for Wegovy, a \$1,300-per-month-per-person proposition."⁷⁵

104. Novo Nordisk has also partnered with think tanks to promote their narrative that obesity is disease for which treatment requires their billion-dollar pharmaceutical drugs.

105. For example, the Milken Institute is a think tank focused on accelerating measurable progress on the path to a meaningful life.⁷⁶

106. As early as 2019, before Ozempic or Wegovy was approved for weight loss, Defendants were publishing articles on the Milken Institute about the "untold story of obesity."⁷⁷

⁷² <https://asmbs.org/corporate-council> (last visited April 12, 2024).

⁷³ <https://stop.publichealth.gwu.edu/membership> (last visited April 12, 2024).

⁷⁴ [https://assets.obesitycareadvocacynetwork.com/TROA_fact_sheet_11_12_21_48098432e0.pdf](https://assets.obesitycareadvocacynetwork.com/TROA_fact_sheet_11_12_21_48098432e0/TROA_fact_sheet_11_12_21_48098432e0.pdf) (last visited April 12, 2024).

⁷⁵ <https://www.fiercepharma.com/marketing/health-group-lambasts-novo-nordisk-60-minutes-paid-news-program-weight-loss-med-wegovy> (last visited April 12, 2024).

⁷⁶ <https://milkeninstitute.org/about> (last visited April 12, 2024).

⁷⁷ <https://milkeninstitute.org/article/untold-story-obesity-collaborating-across-sectors-make-care-happen> (last visited April 12, 2024).

107. Defendants have deceptively promoted their weight loss drugs on television and news segments.

108. For example, Novo Nordisk's drugs were the subject of an investigative report on 60 Minutes that aired New Year's Day of 2023.⁷⁸

109. Complaints have been filed alleging that the "news" piece was in reality a marketing piece in which all physicians interviewed had received payments by Novo Nordisk.⁷⁹

110. The financial relationship between the physicians speaking about Wegovy and Ozempic and Novo Nordisk was not explicitly disclosed.⁸⁰ The reporter stated that the physicians had *advised* Novo Nordisk but failed to state they had been compensated by the company.⁸¹

111. The nonprofit public health advocacy group the Physicians Committee issued a formal complaint that a recent CBS "60 Minutes" segment was a promotion for Novo Nordisk's obesity drug, Wegovy, that was dressed up as a news segment.⁸²

112. The Washington, D.C.-based group has filed a complaint with federal bodies alleging that the CBS "60 Minutes" segment that aired on New Year's Day breached the FDA's "fair balance" rules for drug ads.⁸³

113. The Physician's Committee said in a release that the feature failed to talk about alternatives to the drug or about other weight-loss methods; that only experts "paid by Novo" were used in the program; and that the piece used overly promotional language.⁸⁴

⁷⁸ <https://www.cbsnews.com/news/wegozy-ozempic-explainer-60-minutes-2023-01-01/> (last visited April 12, 2024).

⁷⁹ <https://www.fiercepharma.com/marketing/health-group-lambasts-novo-nordisk-60-minutes-paid-news-program-weight-loss-med-wegovy> (last visited April 12, 2024).

⁸⁰ <https://fair.org/home/60-minutes-weight-loss-tip-dont-bite-the-hand-that-feeds-you/> (last visited April 12, 2024).

⁸¹ *Id.*

⁸² *Id.*; <https://www.pcrm.org/news/news-releases/cbs-60-minutes-news-segment-was-unlawful-weight-loss-drug-ad-physicians> (last visited April 12, 2024)

⁸³ *Id.*

⁸⁴ *Id.*

114. The FDA is currently investigating the marketing practices of Novo Nordisk.⁸⁵

115. Novo Nordisk has spent millions of dollars delivering their message to physicians, healthcare providers, and consumers.

116. For example, Novo Nordisk spent over \$33,000,000 in 2022 on traditional physician marketing and detailing according to Open Payments Data.⁸⁶

117. Defendants have directly and indirectly partnered with telehealth providers to promote their weight loss drugs.

118. This includes a 2019 direct partnership between Novo Nordisk and Noom, a leading behavior weight loss company.⁸⁷ After Saxenda was approved for weight loss, Noom joined with Novo Nordisk again to develop custom programs to accompany this weight loss medication.⁸⁸

119. In 2021, Novo Holdings participated in a \$540 million round of financing with Noom.⁸⁹ At that time, Novo Holdings tweeted that it “is pleased to note that it has participated in the \$540 million Series F round in @noom, a leading digital health platform...”.⁹⁰

120. Novo Holdings currently lists on its website that it has “venture investments” in Noom.⁹¹

121. Noom Med now provides to consumers, using physicians hired by Noom, prescriptions for weight loss directly to patients.⁹²

⁸⁵ <https://www.pcrm.org/news/news-releases/fda-confirms-investigation-novo-nordisk-ad-posed-60-minutes-story-about-weight> (last visited April 12, 2024)

⁸⁶ <https://openpaymentsdata.cms.gov/company/100000000144> (last visited April 12, 2024)

⁸⁷ <https://www.prnewswire.com/in/news-releases/novo-nordisk-and-noom-to-partner-around-digital-health-solutions-to-help-people-with-obesity-lose-weight-and-keep-it-off-811725389.html> (last visited April 12, 2024).

⁸⁸ <https://www.noom.com/blog/in-the-news/noom-announces-two-new-studies-on-impact-of-mobile-coaching-on-binge-eating-disorder-and-obesity/> (last visited April 12, 2024).

⁸⁹ <https://www.businesswire.com/news/home/20210525005492/en/Noom-Announces-540-Million-in-Growth-Funding-to-Further-Accelerate-Expansion-of-its-Digital-Health-Platform> (last visited April 12, 2024)

⁹⁰ <https://twitter.com/novoholdings/status/1397170264702599171> (last visited April 12, 2024)

⁹¹ <https://novoholdings.dk/investments/noom/> (last visited April 12, 2024)

⁹² <https://abcnews.go.com/GMA/Wellness/noom-joins-weight-watchers-offering-medications-wegovy-weight/story?id=99841160> (last visited April 12, 2024).

122. Noom Med promotes off label usage of these weight loss drugs on its website.⁹³

123. Noom currently has over 45 million users.⁹⁴

124. Other telehealth providers have jumped on board the band wagon in offering prescriptions directly to consumers for Defendants' weight-loss medications.

125. This includes Weight Watchers, who purchased telehealth startup Sequence for \$132,000,000 in order to provide weight loss medications to its subscribers.⁹⁵

126. There are currently over 3.5 million Weight Watchers subscribers.⁹⁶

127. It also includes Calibrate, yet another telehealth provider for weight loss medications, which raised \$100 million in capital funding from investors in 2021.

128. Calibrates' clinical advisory board includes Dr. Fatima Cody Stanford.⁹⁷

129. Dr. Cody Stanford is an obesity specialist that frequently speaks on behalf of Novo Nordisk and has received payments directly from Novo Nordisk.⁹⁸ Upon information and belief, Dr. Cody Stanford is one of the highest paid key opinion leaders for Novo Nordisk.

130. This financial and professional conflict of interest is not disclosed on Calibrate's website.

131. This same clinical advisory board member, speaker, and promoter of Novo Nordisk is one of the doctors who appeared on the controversial 60 minutes news segment discussed above.

⁹³ <https://www.noom.com/med/> (last visited April 12, 2024).

⁹⁴ <https://exitsandoutcomes.com/free-excerpt-from-the-noom-report-a-45-million-moat/> (last visited April 12, 2024).

⁹⁵ <https://www.usatoday.com/story/news/health/2023/03/07/weightwatchers-sequence-wegovy-obesity-weight-loss-drugs/11415201002/> (last visited April 12, 2024).

⁹⁶ <https://finance.yahoo.com/news/ww-international-inc-announces-first-200100340.html#:~:text=%E2%80%9CWe%20expect%20to%20end%202023,including%203.5%20million%20WeightWatchers%20subscribers.> (last visited April 12, 2024).

⁹⁷ <https://www.joincalibrate.com/about-us> (last visited April 12, 2024).

⁹⁸ <https://openpaymentsdata.cms.gov/physician/807348> (last visited April 12, 2024).

99



News reports have recognized that such marketing, particularly with telehealth providers, is a “gray area.”¹⁰⁰

132. Their full financial relationship is not disclosed on Defendants’ website.

133. Nor has Dr. Stanford disclosed this relationship in other seemingly independent publications arguing that obesity is a chronic disease that necessitates weight loss medications.¹⁰¹

134. Collectively, the telehealth providers that Novo Nordisk directly and indirectly partners with and/or promotes account for approximately half of all weight loss prescriptions in 2022.¹⁰²

135. In sum, the Novo Nordisk Defendants promoted the safety, efficacy, and sale of Ozempic and Wegovy in the United States on its websites, in press releases, through in-person presentations, through the drug’s label, in print materials, on social media, advocacy groups,

⁹⁹ <https://mronline.org/2023/02/13/60-minutes-weight-loss-tip/> (last visited April 12, 2024).

¹⁰⁰ https://www.statnews.com/2023/04/06/weight-loss-drugs-wegovy-ro-telehealth-ozempic/?utm_campaign=morning_rounds&utm_medium=email&_hsmi=253265291&_hsenc=p2ANqtz-6H01FfkCg2JOnqJnju52tvRIJrTnn-KTwSkzAv1qkbBHi4MR2mN8wdPsbzj6Csbzm5s5M56muD-1rjaA-IF60zzjN1A&utm_content=253265291&utm_source=hs_email (last visited April 12, 2024).

¹⁰¹ <https://www.statnews.com/2022/01/06/recognizing-obesity-as-a-disease-is-a-step-toward-health-equity/> (last visited April 12, 2024).

¹⁰² <https://www.statnews.com/2023/08/10/wegovy-ozempic-weight-loss-telehealth-prescriptions/>

lobbying groups, celebrity partnerships, telehealth partnerships, key opinion leaders, and through other public outlets.

136. Novo Nordisk's comprehensive, immersive marketing has left no stone unturned in delivering their message that physicians and patients must use their drugs to treat obesity.

III. Marketing Works: Novo Nordisk's Rampant Promotion Result in Thousands of Prescriptions and Billions in Sales

137. As a result of the Novo Nordisk Defendants' all-encompassing advertising and promotion efforts, Ozempic and Wegovy are widely prescribed throughout the United States.

138. As of August 10, 2023, Novo Nordisk reported that in the first six months of 2023 sales of Wegovy soared 344% in the U.S. to nearly \$1.7 billion, while sales of Ozempic jumped 50% to more than \$3.7 billion.¹⁰³

139. In July of 2021, doctors in the US wrote 94,000 prescriptions a week for Wegovy and 62,000 a week for Ozempic.¹⁰⁴

140. It has been reported that the huge demand created by extensive marketing has led to rampant off-label usage and "gaming" the system to allow for insurance coverage.¹⁰⁵

141. On a year-end earnings call in 2022, Novo Nordisk cited worldwide market growth of fifty percent, with almost forty thousand new Wegovy prescriptions being written every week.¹⁰⁶

¹⁰³ <https://www.cnbc.com/2023/09/09/big-pharma-blockbuster-obesity-drug-battle-is-headed-for-100-billion.html#:~:text=Novo%20traded%20earnings%20jabs%20with,to%20more%20than%20%243.7%20billion.> (last visited April 12, 2024).

¹⁰⁴ <https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html> (last visited April 12, 2024).

¹⁰⁵ *Id.*

¹⁰⁶ <https://www.newyorker.com/magazine/2023/03/27/will-the-ozempic-era-change-how-we-think-about-being-fat-and-being-thin> (last visited April 12, 2024).

142. The number of prescriptions filled reached an all-time high of 373,000 in one week in February of 2023, with more than half of those being new prescriptions.¹⁰⁷

143. In June 2023, it was reported that new prescriptions for Ozempic had surged by 140 percent from the prior year.¹⁰⁸

144. This surge has reshaped Denmark's economy as the country has reaped huge profits from the sale of the drug, which is now solely responsible for the country's economic growth.¹⁰⁹

145. Wegovy hit such a high demand that the company was not able to make enough, the company's spokeswoman Ambre James- Brown said.¹¹⁰

146. There is now a shortage for the drugs, including those for people who have diagnosed Type II diabetes.¹¹¹

147. Ozempic and Wegovy have become so popular, Novo Nordisk has recently limited shipment to the US and paused advertising to address shortages.¹¹²

IV. Deceptive Marketing: Defendants Continuously Spread Misleading Marketing to Alter Perceptions of Ozempic and Wegovy's Safety Risks.

148. Despite Defendants focus on BMI and their marketing of Ozempic and Wegovy as health-promoting drugs, overall health is more than a simple number.

¹⁰⁷ <https://www.cnn.com/2023/03/17/health/ozempic-shortage-tiktok-telehealth/> (last visited April 12, 2024).

¹⁰⁸ <https://www.washingtonpost.com/business/2023/06/11/weight-loss-ozempic-wegovy-insurance/> (last visited April 12, 2024).

¹⁰⁹ https://www.nytimes.com/2023/08/28/business/denmark-ozempic-wegovy.html?action=click&pgtype=Article&state=default&module=styl&n-weight-loss-drugs&variant=show®ion=MAIN_CONTENT_1&block=storyline_top_links_recirc (last visited April 12, 2024).

¹¹⁰ <https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html> (last visited April 12, 2024).

¹¹¹ <https://www.forbes.com/sites/brianbushard/2023/09/16/shortage-of-weight-loss-drugs-like-wegovy-and-ozempic-persist-and-could-for-some-years/?sh=191877ce631e> (last visited April 12, 2024)

¹¹² <https://www.theatlantic.com/health/archive/2023/05/ozempic-teen-obesity-treatment-health-promises-risks/674204/> (last visited April 12, 2024).

149. On June 14, 2023, the AMA adopted a new policy clarifying how body mass index should be used as a measure in medicine.¹¹³

150. The American Medical Association has urged doctors to deemphasize their use of body mass index (BMI) in determining healthy weights for patients.¹¹⁴

151. Due to significant limitations associated with the widespread use of BMI in clinical settings, the AMA suggests that it be used in conjunction with other valid measures of risk such as, but not limited to, measurements of visceral fat, body adiposity index, body composition, relative fat mass, waist circumference and genetic/metabolic factors.¹¹⁵

152. A recent study examined subjects' BMI in relation to their blood pressure, cholesterol levels, and insulin resistance. Nearly a third of people with a "normal" B.M.I. had unhealthy metabolic metrics, and nearly half of those who were technically overweight were metabolically healthy. About a quarter of those who were classified as obese were healthy, too.¹¹⁶

153. In short, BMI is a poor indicator of health outcomes for an individual.¹¹⁷

154. Weight loss as the sole indicator of health has also been rejected by many clinicians in favor of improvements in other health outcomes and the assessing the whole health of an individual.¹¹⁸

¹¹³ <https://www.ama-assn.org/press-center/press-releases/ama-adopts-new-policy-clarifying-role-bmi-measure-medicine> (last visited April 12, 2024).

¹¹⁴ *Id.*

¹¹⁵ *Id.*

¹¹⁶ <https://www.newyorker.com/magazine/2023/03/27/will-the-ozempic-era-change-how-we-think-about-being-fat-and-being-thin> (last visited April 12, 2024).

¹¹⁷ <https://newsroom.uw.edu/resource/why-body-mass-index-doesnt-give-whole-health-picture> (last visited April 12, 2024).

¹¹⁸ <https://link.springer.com/content/pdf/10.1007/s11606-022-07821-w.pdf?pdf=button> (last visited April 12, 2024); <https://newsroom.uw.edu/resource/why-body-mass-index-doesnt-give-whole-health-picture> (last visited April 12, 2024).

155. These clinicians have cautioned that “a lower body weight does not always mean that a person is healthier.”¹¹⁹

156. It’s recognized in the medical community that weight loss achieved by Ozempic and Wegovy is often a result of a significant loss of muscle mass.¹²⁰

157. This loss of muscle mass can lead to sarcopenia, a condition called being “skinny fat,” in which the patient has decreased muscle mass, lessened bone density, and lower resting metabolic rate— all of which results in a loss of strength and functionality.¹²¹

158. Ongoing use of Ozempic and Wegovy for weight loss can lead to malnutrition and key vitamin deficiencies, such a vitamin B12, that can lead to poor health outcomes.¹²²

159. Given these adverse effects on overall health, the National Institute of Care and Excellence (NICE) has recommended that people stop taking Wegovy after 2 years.¹²³

160. The problem, of course, is that individuals immediately begin to gain the weight back once they stop taking Ozempic and Wegovy.¹²⁴

161. Studies show that as the weight rebounds once individuals stop taking Ozempic and Wegovy, the weight gain is predominantly fat and not muscle.

162. Paradoxically, individuals may be lighter than they were initially but have a higher percentage of body fat.¹²⁵ Individuals who are unable or not warned of the need to mitigate this

¹¹⁹ <https://www.healthline.com/health-news/ozempic-muscle-mass-loss> (last visited April 12, 2024).

¹²⁰ <https://www.nbcnews.com/health/health-news/weight-loss-drugs-muscle-loss-rcna84936> (last visited April 12, 2024).

¹²¹ <https://www.healthline.com/health-news/ozempic-muscle-mass-loss> (last visited April 12, 2024).

¹²² <https://www.nytimes.com/2023/04/21/well/eat/ozempic-side-effects-malnutrition.html> (last visited April 12, 2024).

¹²³ National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. *NICE*. Retrieved from: <https://www.nice.org.uk/guidance/ta875/chapter/1-Recommendations> (last visited April 12, 2024).

¹²⁴ <https://www.psychologytoday.com/ie/blog/the-neuroscience-of-eating-disorders/202303/ozempic-and-wegovy-is-semaglutide-a-miracle-weight> (last visited April 12, 2024).

¹²⁵ <https://www.afr.com/policy/health-and-education/lighter-but-fatter-the-ozempic-paradox-20230718-p5dp5w>

muscle loss with dietary changes and strength training can create a loss of muscle mass that accelerates normal ageing of the muscles.¹²⁶

163. Upon information and belief, the weight that is gained back is often visceral fat, which is considered more harmful to health than other types of fat.

164. A trial published by Novo Nordisk showed that after a year participants had gained back two thirds of the weight lost after they stopped taking semaglutide.¹²⁷

165. Novo Nordisk has publicly recognized that most individuals will regain all the weight back within five years of stopping Ozempic or Wegovy.¹²⁸

166. Remarkably, Novo Nordisk has publicly stated that some individuals will regain even more weight after stopping Ozempic or Wegovy than they initially lost.¹²⁹

167. Ozempic and Wegovy's label and marketing materials do not warn about the need to remain on Wegovy or Ozempic permanently to maintain weight loss. Nor do the label and marketing materials warn that once the drug is stopped that the individual may gain even more weight back than they lost and ultimately weigh more than before starting the drug.

168. Wegovy and Ozempic are often marketed as part of a "metabolic reset."¹³⁰

169. However, Novo Nordisk has recognized that GLP-1s do not rewire "your neural networks to really define a new body weight setpoint."¹³¹

¹²⁶ *Id.*

¹²⁷ <https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14725>

¹²⁸ <https://www.cnbc.com/2023/03/29/people-taking-obesity-drugs-ozempic-and-wegovy-gain-weight-once-they-stop-medication.html> (last visited April 12, 2024).

¹²⁹ *Id.*

¹³⁰ <https://www.joincalibrate.com/resources/how-long-does-it-take-to-lose-weight-on-ozempic> (last visited April 12, 2024).

¹³¹ <https://www.cnbc.com/2023/03/29/people-taking-obesity-drugs-ozempic-and-wegovy-gain-weight-once-they-stop-medication.html> (last visited April 12, 2024).

170. Many clinicians recognize that a need to acknowledge that additional factors besides weight influence a person's health trajectory, including healthcare access, stress, poverty, and environmental threats (*e.g.*, chemicals).¹³²

V. Defendants have long known that Ozempic and Wegovy are powerful, dangerous drugs.

171. As previously noted, Ozempic (semaglutide) and Wegovy (semaglutide) belong to a class of drugs called GLP-1 receptor agonists (“GLP-1 RAs”).

172. Medications within the GLP-1 RA class of drugs mimic the activities of physiologic GLP-1, which is a gut hormone that activates the GLP-1 receptor in the pancreas to stimulate the release of insulin and suppress glucagon.¹³³

173. As detailed below, Defendants knew from their required premarket and post-market research and analytics that Ozempic and Wegovy could cause malnutrition, cyclical vomiting, and gastroparesis, gastroenteritis, intestinal obstruction/blockage, ileus, esophageal and bowel injury, DVT and associated pulmonary embolism, gallbladder problems necessitating surgery, and intraoperative aspiration.

174. The Novo Nordisk Defendants have repeatedly failed to warn about the known dangerous side effects of Ozempic and Wegovy. This includes malnutrition, cyclical vomiting, and gastroparesis, gastroenteritis, intestinal obstruction/blockage, ileus, esophageal and bowel injury, DVT and associated pulmonary embolism, gallbladder problems necessitating surgery, and

¹³² <https://www.psychologytoday.com/ie/blog/the-neuroscience-of-eating-disorders/202303/ozempic-and-wegovy-is-semaglutide-a-miracle-weight> (last visited April 12, 2024).

¹³³ Hinnen D, *Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes*, 30(3) *Diabetes Spectr.*, 202-210 (August 2017), available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556578/> (last visited on April 13, 2024).

intraoperative aspiration. All of these conditions can, and have, lead to hospitalization and/or death in patients across America.

175. Some doctors estimate that as many as 10% of patients discontinue use of these drugs due to the severity of side effects.¹³⁴

176. Thousands of adverse event reports have been filed by the public with the FDA Adverse Event Reporting System. As of June 2022, the FDA has posted an alert that both Ozempic and Wegovy had potential safety signals for intestinal obstruction.¹³⁵

177. On September 22, 2023, FDA updated the label for Ozempic to include “ileus,” the medical term for blocked intestines.¹³⁶

178. Wegovy, chemically identical to Ozempic, already carried a warning on ileus.

179. As early as 2014, Defendants knew that Saxenda (liraglutide), Ozempic’s predecessor, caused serious side effects and warned the end user of same.¹³⁷

180. As early as 2019, Defendants knew that Rybelsus (semaglutide), Ozempic’s predecessor, caused serious side effects and warned the end user of same.

181. These side effects for Rybelsus included: nausea, abdominal pain, diarrhea, decreased appetite, vomiting, constipation, pancreatitis, diabetic retinopathy complication, hypoglycemia; acute kidney injury, and hypersensitivity reactions.¹³⁸

¹³⁴ <https://www.cbsnews.com/news/ozempic-side-effects-weight-loss-drugs-wegovy-mounjaro-doctors-warn/> (last visited April 12, 2024).

¹³⁵ <https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/april-june-2022-potential-signals-serious-risksnew-safety-information-identified-fda-adverse-event> (last visited April 12, 2024)

¹³⁶ <https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=2183>; <https://www.healthline.com/health-news/fda-updates-ozempic-label-to-include-blocked-intestines-as-potential-side-effect#:~:text=Ozempic%20Label%20Updated%20to%20Include%20Blocked%20Intestines%20as%20Potential%20Side%20Effect&text=The%20FDA%20is%20warning%20patients,serious%20and%20potentially%20fatal%20condition> (last visited April 12, 2024).

¹³⁷ https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321orig1s000lbl.pdf (last visited April 12, 2024).

¹³⁸ <https://www.novo-pi.com/rybelsus.pdf> (last visited April 12, 2024).

182. According to the FDA Adverse Event Reporting System, Defendants were aware of reports of intestinal obstruction no later than 2019 for Ozempic and/or Wegovy.¹³⁹ These reports to the FDA also stated that many of these patients reporting intestinal obstruction or blockage were hospitalized.¹⁴⁰

183. The Prescribing Information for Ozempic discloses warnings, precautions, and adverse reactions associated with Ozempic, but it does not disclose the risk of severe gastrointestinal events, including gastroparesis and gastroenteritis. Instead, it discloses delayed gastric emptying under the “Drug Interactions” heading and notes that Ozempic “may impact absorption of concomitantly administered oral medications.” Further, under the “Mechanism of Action” section, the Prescribing Information states that “[t]he mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.”¹⁴¹ These statements do not disclose gastroparesis or delayed gastric emptying as risks of taking Ozempic, nor do they disclose gastroparesis as a chronic condition that can result as a consequence of taking Ozempic.

184. The Prescribing Information for Wegovy discloses warnings, precautions, and adverse reactions associated with taking Wegovy, but it does not disclose the risk of severe gastrointestinal events, including gastroparesis and gastroenteritis. Instead, it discloses delayed gastric emptying under the “Drug Interactions” heading and notes that Wegovy “may impact absorption of concomitantly administered oral medications.”¹⁴² These statements do not disclose gastroparesis or delayed gastric emptying as risks of taking Wegovy, nor do they disclose gastroparesis as a chronic condition that can result because of taking Wegovy.

¹³⁹ <https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/8eef7d83-7945-4091-b349-e5c41ed49f99/state/analysis> (last access April 12, 2024).

¹⁴⁰ *Id.*

¹⁴¹ <https://www.novo-pi.com/ozempic.pdf> (last visited April 12, 2024).

¹⁴² https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf (last visited April 12, 2024).

185. Despite their experience and knowledge, Defendants have downplayed the severity of the gastrointestinal events caused by Ozempic, never, for example, warning of the risk of gastroparesis (“paralyzed stomach”), gastroenteritis, or intestinal blockage or obstruction.

186. Gastroparesis is a condition that affects normal muscle movement in the stomach. Ordinarily, strong muscular contractions propel food through the digestive tract. However, in a person suffering from gastroparesis, the stomach’s motility is slowed down or does not work at all, preventing the stomach from emptying properly. Gastroparesis can interfere with normal digestion, and can cause nausea, vomiting, abdominal pain, abdominal bloating, severe dehydration, a feeling of fullness after eating just a few bites, vomiting undigested food, undigested food that hardens and remains in the stomach, acid reflux, changes in blood sugar levels, lack of appetite, weight loss, malnutrition, and a decreased quality of life. There is no cure for gastroparesis.¹⁴³

187. Gastroenteritis refers to inflammation of the stomach and intestines. While viral gastroenteritis is also known as stomach flu, gastroenteritis may also be caused by ingesting medications.¹⁴⁴ Its symptoms include vomiting, nausea, diarrhea, stomach cramps, muscle aches, headaches, and fever.¹⁴⁵ Notably, vomiting and diarrhea can cause dehydration, which is the main complication of gastroenteritis, and which can lead to death.¹⁴⁶

188. At all relevant time periods, Defendants did not disclose any risks associated with severe gastrointestinal events, including the risk of gastroparesis, gastroenteritis, and intestinal

¹⁴³ <https://www.mayoclinic.org/diseases-conditions/gastroparesis/symptoms-causes/syc-20355787> (last visited April 12, 2024).

¹⁴⁴ <https://www.merckmanuals.com/home/digestive-disorders/gastroenteritis/drug-related-gastroenteritis-and-chemical-related-gastroenteritis> (last visited April 12, 2024).

¹⁴⁵ <https://www.mayoclinic.org/diseases-conditions/viral-gastroenteritis/symptoms-causes/syc-20378847> (last visited April 12, 2024)

¹⁴⁶ *Id.*

blockage or obstruction within the “Important Safety Information” section of their promotional website.

189. At all relevant time periods, none of Defendants’ additional advertising or promotional materials warned prescription providers or the general public of the risk of severe gastrointestinal events, including gastroparesis, gastroenteritis, or intestinal blockage or obstruction.

190. A 2011 published article notes that “From extensive studies in experimental animals and humans we have found that GLP-1 also exerts a motility-inhibiting and antispasmodic effect in the gut that was verified in healthy volunteers...”.¹⁴⁷ It is explicitly noted that GLP-1s have slowed down gastric emptying.¹⁴⁸

191. A similar published article in 2013 found that after a review of PubMed articles it was evident that GLP-1s inhibit gastric emptying; notably, they separately found that delayed gastric emptying could lead to malnutrition.¹⁴⁹

192. A 2018 Case report found that liraglutide had caused acute gastroparesis and noted that: “This case highlights the importance of considering drug-induced gastroparesis as an etiology of unexplained upper abdominal pain, nausea, and early satiety, especially in the absence of mechanical obstruction.”¹⁵⁰

¹⁴⁷ Hellström PM. GLP-1 playing the role of a gut regulatory compound. *Acta Physiol (Oxf)*. 2011 Jan;201(1):151-6. doi: 10.1111/j.1748-1716.2010.02150.x. PMID: 20518750; available at <https://pubmed.ncbi.nlm.nih.gov/20518750/> (last visited April 12, 2024).

¹⁴⁸ *Id.*

¹⁴⁹ Luttikhof J, de Ruijter FM, van Norren K, Diamant M, Witkamp RF, van Leeuwen PA, Vermeulen MA. Review article: the role of gastrointestinal hormones in the treatment of delayed gastric emptying in critically ill patients. *Aliment Pharmacol Ther*. 2013 Sep;38(6):573-83. doi: 10.1111/apt.12421. Epub 2013 Jul 23. PMID: 23879699. (last visited April 12, 2024).

¹⁵⁰ Rai P, Madi MY, Dickstein A. Liraglutide-induced Acute Gastroparesis. *Cureus*. 2018 Dec 28;10(12):e3791. doi: 10.7759/cureus.3791. PMID: 30868005; PMCID: PMC6402745; available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402745/pdf/cureus-0010-00000003791.pdf> (last visited April 12, 2024).

193. In August of 2020, medical literature advised that some “patients do not know they have diabetic gastroparesis until they are put on a glucagon-like peptide 1 (GLP-1) receptor agonist such as ... semaglutide ... to manage their blood glucose.” The article went on to explain that “[t]his class of drugs can exacerbate the symptoms of diabetic gastroparesis. ... Thus, GLP-1 receptor agonist therapy is not recommended for people who experience symptoms of gastroparesis.”¹⁵¹

194. In 2021, a case report was published regarding a 52-year-old female who had been taking weekly semaglutide injections approximately one month prior to the onset of gastroparesis symptoms. The case report authors concluded that “thorough history taking revealed the cause [of gastroparesis] to be medication induced.”¹⁵²

195. A second case report also published in 2021 involved a 57-year-old female who had been taking weekly dulaglutide injections (another GLP-1 receptor agonist) for 15 months and suffering from bloating, nausea and vomiting for 12 of those months. Testing revealed delayed gastric emptying which improved with cessation of dulaglutide.¹⁵³

196. In 2022 a large, population-based study indicated that the use of GLP-1 RAs was associated with an increased risk of intestinal obstruction.¹⁵⁴

¹⁵¹ Young CF, Moussa M, Shubbrook JH, *Diabetic Gastroparesis: A Review*, Diabetes Spectr. 2020 Aug; 33(3): 290–297, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428659/> (last visited April 12, 2024).

¹⁵² Kalas MA, Galura GM, McCallum RW, *Medication-Induced Gastroparesis: A Case Report*, J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9: 23247096211051919, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529310/> (last visited April 12, 2024).

¹⁵³ Kalas MA, Galura GM, McCallum RW, *Medication-Induced Gastroparesis: A Case Report*, J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9: 23247096211051919, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529310/> (last visited April 12, 2024).

¹⁵⁴ Faillie, J.-L., Yin, H., Yu, O.H.Y., Herrero, A., Altwegg, R., Renoux, C. and Azoulay, L. (2022), Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes. Clin. Pharmacol. Ther., 111: 272–282. <https://doi.org/10.1002/cpt.2430> (last visited April 12, 2024).

197. In addition, in March of 2022, the FDA modified the warning label of Ozempic to include a specific warning about the risk of gallbladder disease associated with the drug.¹⁵⁵ Gallbladder disease has been associated with surgery and other complications.

198. On June 29, 2023, the American Society of Anesthesiologists issued a warning that patients taking Ozempic should stop the medication at least a week before elective surgery because Ozempic and other GLP-1 agonists “delay gastric (stomach) emptying” and “the delay in stomach emptying could be associated with an increased risk of regurgitation and aspiration of food into the airways and lungs during general anesthesia and deep sedation.”¹⁵⁶

199. On July 25, 2023, it was reported that patients taking Ozempic had been diagnosed “with severe gastroparesis, or stomach paralysis, which their doctors think may have resulted from or been exacerbated by the medication they were taking, Ozempic.” Additionally, “[t]he US Food and Drug Administration said it has received reports of people on the Ozempic experiencing stomach paralysis[.]”¹⁵⁷

200. Case reports continue to be published regarding the use of semaglutide and intraoperative aspirations.¹⁵⁸

201. In June 2021, a comprehensive meta-analysis showed nearly a four-fold increased risk of DVT when taking semaglutide.¹⁵⁹ DVT, or deep vein thrombosis, is associated with pulmonary embolism and other serious complications, including death.

¹⁵⁵ https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf

¹⁵⁶ <https://www.asahq.org/about-as/newsroom/news-releases/2023/06/patients-taking-popular-medications-for-diabetes-and-weight-loss-should-stop-before-elective-surgery> (last visited April 12, 2024).

¹⁵⁷ <https://www.cnn.com/2023/07/25/health/weight-loss-diabetes-Ozempic-gastroparesis/index.html> (last visited April 12, 2024).

¹⁵⁸ <https://pubmed.ncbi.nlm.nih.gov/36977934/> (last visited April 12, 2024).

¹⁵⁹ Yin DG, Ding LL, Zhou HR, Qiu M, Duan XY. Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials. *Endocr J.* 2021 Jun 28;68(6):739-742. doi: 10.1507/endocrj.EJ21-0129. Epub 2021 May 22. PMID: 34024887.

202. At all relevant time periods, the Novo Nordisk Defendants made, distributed, marketed, and/or sold Ozempic and/or Wegovy without adequate warning to Plaintiff's prescribing physician(s) and/or Plaintiff that Ozempic and/or Wegovy was associated with and/or could cause severe gastrointestinal issues including gastroparesis, gastroenteritis, and intestinal blockage or obstruction, ileus, malnutrition, esophageal and bowel injury, DVT, intraoperative aspiration, and death.

203. Defendants knew of the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues including gastroparesis, gastroenteritis, and intestinal blockage or obstruction, ileus, malnutrition, esophageal and bowel injury, DVT, intraoperative aspiration, and death. Defendants' knowledge derived from their clinical studies, case reports, and the medical literature, including the medical literature and case reports referenced above in this Complaint.

204. Upon information and belief, Defendants ignored the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues including gastroparesis, gastroenteritis, and intestinal blockage or obstruction, ileus, malnutrition, esophageal and bowel injury, DVT, intraoperative aspiration, and death.

205. Defendants' failure to disclose information that they possessed regarding the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues including gastroparesis, gastroenteritis, and intestinal blockage or obstruction, ileus, malnutrition, esophageal and bowel injury, DVT, intraoperative aspiration, and death, rendered the warnings for this medication inadequate.

206. By reason of the foregoing acts and omissions, Plaintiff was and still is caused to suffer from severe gastrointestinal issues, as well as other severe and personal injuries which are

permanent and lasting in nature, physical pain, and mental anguish, including diminished enjoyment of life, as well as the need for lifelong medical treatment, monitoring and/or medications, and fear of developing any of the above-named health consequences.

207. Defendants also fail to provide adequate instructions for use and warnings and precautions for Ozempic and Wegovy, including failing to warn that a patient needs to remain permanently on the drug or the weight will be regained within a one to five year period. Nor do the Defendants provide instructions on how to safely use the drug to mitigate harms, including how to safely monitor the patient for adverse effects and how to safely take the patient off the drug without causing a worsening of those adverse events, such as severe gastrointestinal issues including gastroparesis, gastroenteritis, and intestinal blockage or obstruction, ileus, malnutrition, esophageal and bowel injury, DVT, intraoperative aspiration, and death.

VI. The Dark Side of Ozempic and Wegovy

208. It has been recognized in the media that in the aftermath of the marketing frenzy created by Novo Nordisk that the full risks of these drugs are not understood or readily available to the average patient—and perhaps the average provider.¹⁶⁰

209. For example, one physician has stated that “I suspect the drug companies are downplaying this risk because women are probably the biggest part of the market share,” she said. “The world doesn’t value women, and this is seen in women’s health as well.”¹⁶¹

210. Strikingly, Novo Nordisk’s own hired spokesperson and consultant has stated on national television that “[d]octors do not understand obesity.”¹⁶²

¹⁶⁰ <https://www.vox.com/science/23683383/ozempic-pregnancy-risks-side-effect-semaglutide-wegovy> (last visited April 12, 2024).

¹⁶¹ <https://www.vox.com/science/23683383/ozempic-pregnancy-risks-side-effect-semaglutide-wegovy> (last visited April 12, 2024).

¹⁶² <https://www.cbsnews.com/news/weight-loss-obesity-drug-2023-01-01/> (last visited April 12, 2024).

211. It is unclear how Novo Nordisk would expect a doctor to understand the mechanism of their weight loss drug—and its corresponding risks—if they do not understand the condition it is supposed to treat.

212. Defendants have much greater knowledge of their obesity drugs, including their dangerous risks, than the medical community or American public.

213. This includes the fact that female sex is an independent risk factor associated with an increased risk of adverse effects when taking GLP-1s.¹⁶³

214. Neither the Ozempic nor Wegovy label warns that being female increases the risk of suffering adverse effects when taking these drugs.

215. Recently, news articles have begun to publicize the dark side of these drugs.¹⁶⁴

216. Consumers of Ozempic and Wegovy are reporting major health problems, including gastroparesis, stomach paralysis, gastroenteritis, DVT (deep vein thrombosis), gallbladder problems necessitating surgery, intraoperative aspiration, and intestinal blockage or obstruction.¹⁶⁵

217. Consumers are not aware that taking Ozempic or Wegovy can lead to severe malnutrition.¹⁶⁶

¹⁶³ <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950819/> (“In contrast, female sex appears to be a well-recognized independent factor linked to greater weight loss achievement after treatment with GLP-1 RAs. **This is also the case for adverse events resulting from the use of these medications**, which appear to manifest in higher percentages in women, mainly affecting the GI tract.”) (emphasis added) (last visited April 12, 2024).

¹⁶⁴ <https://www.cnn.com/2023/06/07/opinions/ozempic-weight-loss-drug-diet-culture-wellness-carr-goldynia-sole-smith/index.html> (last visited April 12, 2024).

¹⁶⁵ <https://fda.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/8eef7d83-7945-4091-b349-e5c41ed49f99/state/analysis> (last visited April 12, 2024).

¹⁶⁶ An Extreme Risk of Taking Ozempic: Malnutrition – The New York Times (<https://www.nytimes.com/2023/04/21/well/eat/ozempic-side-effects-malnutrition.html>) (last visited April 12, 2024).

218. Consumers are not aware that taking Ozempic and Wegovy can lead to severe muscle loss.¹⁶⁷

219. Muscle loss (sarcopenia) can lead to death.¹⁶⁸

220. Consumers are not warned that if they stop taking Ozempic and/or Wegovy, they will quickly regain the weight back.

221. Nor are consumers warned that the weight regain is predominantly fat and not muscle – essentially rendering the consumer worse off than before they started the drug.

222. Other industry experts, including physicians, believe that there needs to be greater awareness of the risks of Ozempic and Wegovy.¹⁶⁹

223. Yet Defendants have continued selling Ozempic and Wegovy to a point where there are mass shortages and waitlists.¹⁷⁰

224. This is despite the fact the FDA has investigated and found “objectionable” conditions at Novo Nordisk’s Clayton, N.C. manufacturing plant that is responsible for making weight loss drugs like Ozempic and Wegovy.¹⁷¹

225. This is not the first time the FDA has cited a company for failures related to the manufacturing of Wegovy and Ozempic. In January 2021, a US FDA Form 483 revealed that Catalent failed to implement sustainable corrective action and preventive action and had

¹⁶⁷ <https://www.healthline.com/health-news/ozempic-muscle-mass-loss> (last visited April 12, 2024).

¹⁶⁸ <https://my.clevelandclinic.org/health/diseases/23167-sarcopenia#:~:text=Sarcopenia%20affects%20your%20musculoskeletal%20system,risk%20of%20complications%20including%20death> (last visited April 12, 2024).

¹⁶⁹ <https://www.vox.com/science/23683383/ozempic-pregnancy-risks-side-effect-semaglutide-wegovy> (last visited April 12, 2024).

¹⁷⁰ https://www.nytimes.com/2023/08/28/business/denmark-ozempic-wegovy.html?action=click&pgtype=Article&state=default&module=style&n-weight-loss-drugs&variant=show®ion=MAIN_CONTENT_1&block=storyline_top_links_recirc (last visited April 12, 2024).

¹⁷¹ [https://www.investors.com/news/technology/novo-nordisk-stock-skids-as-report-finds-objectionable-conditions-at-wegovy-plant/#:~:text=Novo%20Nordisk%20\(NVO\)%20stock%20skidded,diabetes%20and%20weight%20loss%20drugs](https://www.investors.com/news/technology/novo-nordisk-stock-skids-as-report-finds-objectionable-conditions-at-wegovy-plant/#:~:text=Novo%20Nordisk%20(NVO)%20stock%20skidded,diabetes%20and%20weight%20loss%20drugs) (last visited April 12, 2024).

inadequate maintenance at a Catalent fill/finish facility.¹⁷² Novo Nordisk confirmed that “a contract manufacturer doing syringe filling on the GLP-1 med had temporarily halted deliveries following a good manufacturing practices glitch.”¹⁷³

226. Defendants are profiting while the end consumers, mostly women, are suffering.

PARTY PLAINTIFF

227. Plaintiff Angela Hall is a resident of Catlettsburg, Boyd County, in the Commonwealth of Kentucky and is currently 47 years old.

228. In May of 2023, Plaintiff Angela Hall started taking Wegovy after consulting with Timothy Caudill, an Advanced Practice Registered Nurse (APRN) at King’s Daughters Medical Center, who prescribed the Wegovy that was used by Plaintiff Angela Hall.

229. In December of 2023, Plaintiff Angela Hall went to the emergency room with severe abdominal pain, nausea, and vomiting.

230. Plaintiff Angela Hall was subsequently admitted to the hospital on multiple occasions and diagnosed with small bowel obstruction and GLP-1 gastroparesis.

231. Both of Plaintiff Angela Hall’s hospital admissions due to her injuries resulted in multi-day hospitalizations.

232. Even after discharge, Plaintiff Angela Hall has continued to have appointments for follow-up care related to her injuries, including appointments with gastroenterologists.

233. As a result of using Wegovy, Plaintiff Angela Hall was caused to suffer from gastroparesis and small bowel obstruction and, as a result, sustained severe and permanent personal injuries, pain, suffering, and emotional distress, and incurred medical expenses.

¹⁷² <https://bioprocessintl.com/bioprocess-insider/regulations/fda-483-shows-7-observations-at-catalent-fill-finish-plant-in-belgium/> (last visited April 12, 2024); <https://www.fiercepharma.com/manufacturing/inside-catalent-fda-citation-allegedly-at-heart-novo-nordisk-s-wegovy-supply-hiccup> (last visited April 12, 2024).

¹⁷³ *Id.*

234. At all times material to the above, the Wegovy label failed to adequately warn Plaintiff Angela Hall and her medical providers of the true risks of taking Wegovy.

235. At all times material to the above, the Wegovy marketing and advertising failed to adequately warn Plaintiff Angela Hall and her medical providers of the true risks of taking Wegovy.

COUNT I: NEGLIGENCE

236. Plaintiff incorporates by reference each allegation set forth in preceding paragraphs as if fully stated herein.

237. Defendants, directly or indirectly, caused Wegovy and/or Ozempic to be sold, distributed, packaged, labeled, marketed, promoted, and used by Plaintiff. At all relevant times, Defendants registered, researched, distributed, marketed, overpromoted, and sold Wegovy and/or Ozempic within the Commonwealth of Kentucky and throughout the United States.

238. At all relevant times, Defendants had a duty to exercise reasonable care in the manufacture, marketing, advertisement, supply, storage, transport, packaging, sale, and distribution of Wegovy and/or Ozempic products, including the duty to take all reasonable steps necessary to manufacture, promote, and/or sell a product that did not cause users to suffer from unreasonable, dangerous side effects without an adequate warning—when used alone or in foreseeable combination with other drugs.

239. At all relevant times, Defendants knew, or in the exercise of reasonable care, should have known of the hazards and dangers associated with Wegovy and/or Ozempic, and specifically that use of these drugs could cause malnutrition, cyclical vomiting, gastroparesis, gastroenteritis, intestinal obstruction/blockage, ileus, DVT and associated pulmonary embolism, gallbladder

problems necessitating surgery, esophageal injury, bowel injury, intraoperative aspiration, and death.

240. At all relevant times, Defendants knew, or in the exercise of reasonable care, should have known that the use of Wegovy and/or Ozempic could cause Plaintiff's injuries, and thus, created a dangerous and unreasonable risk of injury to the users of these products that Defendants did not warn of.

241. Defendants knew, or in the exercise of reasonable care, should have known that users and consumers were unaware of the risks and magnitude of the risks associated with the use of Wegovy and/or Ozempic.

242. Defendants breached their duty of care to Plaintiff and Plaintiff's treating physicians, in the warning, testing, monitoring, and pharmacovigilance of Ozempic and Wegovy.

243. Defendants, individually and collectively, had a duty to control the quality of their products and use due care in the preparation, design, development, and manufacture of their products but failed to do so.

244. In disregard of their duties, Defendants committed one or more of the following negligent acts or omissions:

- a. Manufacturing, producing, overpromoting, marketing, formulating, creating, developing, designing, selling, and distributing Ozempic and Wegovy, without thorough and adequate pre- and post-market testing of the product;
- b. Manufacturing, producing, overpromoting, marketing, advertising, formulating, creating, developing, and distributing Ozempic and Wegovy, and upon information and belief, while negligently and intentionally concealing and failing to disclose clinical data which demonstrated the risk of serious harm associated with the use of Ozempic and Wegovy;

- c. Failing to undertake sufficient studies and conduct necessary tests to determine whether or not Ozempic and Wegovy were safe for their intended use;
- d. Upon information and belief, failing to disclose and warn of the product defect to the regulatory agencies, the medical community, and consumers that Defendants knew and had reason to know that Ozempic/Wegovy was indeed unreasonably unsafe and unfit for use by reason of the product's defect and risk of harm to its users;
- e. Failing to warn Plaintiff, the medical and healthcare community, and consumers that Ozempic and Wegovy's risk of harm was unreasonable and that there were safer and effective alternative products available to Plaintiff and other consumers;
- f. Failing to provide adequate instructions, guidelines, and safety precautions to those persons to whom it was reasonably foreseeable would use Ozempic and Wegovy;
- g. Advertising, marketing, and recommending the use of Ozempic and Wegovy, while concealing and failing to disclose or warn of the dangers known by Defendants to be connected with, and inherent in, the use of Ozempic and Wegovy;
- h. Representing that Ozempic and Wegovy were safe for weight loss when in fact Defendants knew and/or should have known the products were not safe for those purposes;
- i. Continuing to manufacture and sell Ozempic and Wegovy with the knowledge that Ozempic and Wegovy, when used for weight loss, were unreasonably unsafe and dangerous;
- j. Failing to use reasonable and prudent care in the design, research, testing, manufacture, and development of Ozempic and Wegovy so as to avoid the risk of serious harm associated with the use of Ozempic and Wegovy. Failing to design and manufacture Ozempic and Wegovy so as to ensure the drugs were at least as safe and effective as other similar products;

- k. Failing to ensure that Ozempic and Wegovy were accompanied by proper and accurate warnings about the risk of severe gastrointestinal problems including gastroparesis.
- l. Failing to ensure that Ozempic and Wegovy were accompanied by proper and accurate warnings about possible adverse side effects associated with the use of Ozempic and Wegovy and that use of Ozempic and Wegovy created a high risk of severe injuries; and
- m. Failing to conduct adequate testing, including pre-clinical and clinical testing, and post-marketing surveillance to determine the safety of Ozempic and Wegovy.

245. A reasonable manufacturer, designer, distributor, promoter, or seller under the same or similar circumstances would not have engaged in the aforementioned acts and omissions.

246. As a direct and proximate result of Defendants' negligent testing, monitoring, and pharmacovigilance of Ozempic and Wegovy, Defendants introduced a drug into this Commonwealth in an unreasonably dangerous condition that they knew or should have known would cause serious and severe complications in people, including Plaintiff Angela Hall's injuries including gastroparesis, an incurable condition, and Plaintiff has been injured catastrophically and sustained severe and permanent pain, suffering, and impairment, loss of enjoyment of life, loss of care, comfort, and economic damages.

247. Defendants acted maliciously and with conscious and/or deliberate disregard of the foreseeable harm caused by use of their products. Defendants' conduct as alleged herein was done with reckless disregard for human life, oppression, and malice so as to warrant the imposition of punitive damages.

248. The aforementioned negligence and wrongs done by Defendants were aggravated by the kind of grossly negligent conduct and disregard for the rights of others, the public, and

Plaintiff, for which the law allows the imposition of exemplary or punitive damages, in that Defendants' conduct involved an extreme degree of risk, considering the probability and magnitude of the potential harm to others, and Defendants failed to exercise reasonable care and proceeded with a wanton or reckless disregard for the lives, rights, safety, property, or welfare of others, including Plaintiff.

249. Defendants are liable in tort to Plaintiff for their wrongful conduct pursuant to Kentucky law.

250. As a direct and proximate result of one or more of the above-stated negligent acts by Defendants, Plaintiff suffered bodily injuries and consequent economic and other losses, including pain and suffering, loss of a normal life, medical expenses, lost income and disability, and punitive damages.

COUNT II: NEGLIGENCE – FAILURE TO WARN

251. Plaintiff incorporates by reference each allegation set forth in preceding paragraphs as if fully stated herein.

252. Ozempic and/or Wegovy are products within the meaning of Kentucky products liability law.

253. Ozempic and/or Wegovy was expected to reach, and did reach, users and/or consumers, including Plaintiff, without substantial change in the defective and unreasonably dangerous condition in which it was sold or distributed.

254. Defendants owed Plaintiff and other Ozempic and/or Wegovy users a duty to exercise reasonable care in marketing, advertising, promoting, distributing and/or selling Ozempic and/or Wegovy.

255. Defendants advertised and promoted Ozempic and/or Wegovy for the purpose of weight loss and diabetes control.

256. At all times material, Plaintiff and Plaintiff's healthcare providers used Wegovy in a manner intended and/or foreseeable to Defendants.

257. A reasonable patient or consumer of Ozempic and/or Wegovy would expect the drug to be free of significant defects.

258. Defendants knew or had reason to know of facts establishing that Ozempic and/or Wegovy posed a significant risk of malnutrition, cyclical vomiting, gastroparesis, gastroenteritis, intestinal obstruction/blockage, ileus, DVT and associated pulmonary embolism, gallbladder problems necessitating surgery, intraoperative aspiration and death, and deliberately proceeded to act, or failed to act, in conscience disregard of, or indifference, to that risk.

259. At all times relevant hereto, the defective nature of Ozempic and/or Wegovy was known to Defendants, or reasonably and scientifically knowable to them, through appropriate research and testing by known methods, at the time they distributed, supplied, or sold their respective products, and not known to ordinary physicians who would be expected to prescribe the drug to their patients.

260. In disregard of their duty to timely warn consumers of health risks associated with Ozempic and/or Wegovy, Defendants committed one or more of the following negligent acts or omissions:

- a. Failing to properly and adequately warn and instruct Plaintiff and Plaintiff's treating physicians that Wegovy and/or Ozempic was designed and/or manufactured in a way that it could cause injuries and damages, including lasting and permanent gastrointestinal injuries;

- b. Failing to timely disclose to Plaintiff and Plaintiff's treating physicians the risks of increased risk of severe gastrointestinal events (e.g., gastroparesis, gastroenteritis, intestinal blockage, ileus, bowel or esophageal injury, cyclical vomiting, and malnutrition), DVT, intraoperative aspiration, gallbladder problems necessitating surgery, and/or death, as well as the need to permanently stay on the drug or the weight will be regained;
- c. Failing to timely warn Plaintiff and Plaintiff's treating physicians that a detailed lab work and patient history should be obtained before starting Ozempic and/or Wegovy.

261. At all relevant times, the labels for Wegovy and/or Ozempic were inadequate because they did not warn and/or adequately warn of all possible adverse side effects associated with the use of Wegovy and/or Ozempic, including the increased risk of severe gastrointestinal events (e.g., gastroparesis, gastroenteritis, intestinal blockage, ileus, bowel or esophageal injury, cyclical vomiting, and malnutrition), DVT, intraoperative aspiration, gallbladder problems necessitating surgery, and/or death, as well as the need to permanently stay on the drug or the weight will be regained.

262. The labels for Wegovy and/or Ozempic were inadequate because they did not contain adequate instructions for use such that a physician and patient could make an informed prescribing decision, adequately monitor the patient while using, and mitigate potential harms from the use of Wegovy and/or Ozempic.

263. At all relevant times, the labels for Wegovy and/or Ozempic were inadequate because they did not warn and/or adequately warn that Wegovy and/or Ozempic had not been sufficiently and/or adequately tested for safety risks, including severe gastrointestinal events (e.g., gastroparesis, gastroenteritis, intestinal blockage, ileus, bowel or esophageal injury, cyclical vomiting, and malnutrition), as well as DVT, gallbladder problems necessitating surgery, intraoperative aspiration, and/or death.

264. The labels for Wegovy and/or Ozempic were inadequate because they did not warn and/or adequately warn of all possible adverse side effects concerning the failure and/or malfunction of Wegovy and/or Ozempic.

265. The labels for Wegovy and/or Ozempic were inadequate because they did not warn and/or adequately warn of the severity and duration of such adverse effects, as the warnings given did not accurately reflect the symptoms, or severity of the side effects.

266. At all relevant times, communications made by Defendants to Plaintiff and Plaintiff's prescribing physician(s) were inadequate because Defendants failed to warn and/or adequately warn of all possible adverse side effects associated with the use of Wegovy and/or Ozempic, including the increased risk of severe gastrointestinal events (e.g., gastroparesis, gastroenteritis, intestinal blockage, ileus, bowel/esophageal injury, cyclical vomiting, and malnutrition), DVT, gallbladder problems necessitating surgery, intraoperative aspiration, and/or death.

267. At all relevant times, communications made by Defendants to Plaintiff and Plaintiff's prescribing physician(s) were inadequate because Defendants failed to warn and/or adequately warn that Wegovy and/or Ozempic had not been sufficiently and/or adequately tested for safety risks, including severe gastrointestinal events (e.g., gastroparesis and gastroenteritis, intestinal blockage, bowel/esophageal injury, cyclical vomiting, and malnutrition), DVT, gallbladder problems necessitating surgery, intraoperative aspiration, and/or death.

268. Defendants' failure to warn of the above was the proximate cause of Plaintiff's injuries, harm, and economic loss, from which Plaintiff continues to suffer.

269. Defendants' failure to warn of the significant risks of Wegovy and/or Ozempic use prevented Plaintiff and Plaintiff's treating physicians from conducting a proper assessment of the risks and benefits of using Wegovy and/or Ozempic.

270. Had Plaintiff and/or Plaintiff's treating physicians been properly warned of the significant risks of Wegovy and/or Ozempic, they would not have elected to begin and/or continue Wegovy therapy.

271. Reasonable, safer alternative treatments were available to Plaintiff and/or Plaintiff's treating physicians had they been warned of these significant risks.

272. Defendants are liable in tort to Plaintiff for their wrongful conduct pursuant to Kentucky law.

273. As a direct, foreseeable and proximate result of Defendants' failure to warn of the significant risks associated with Wegovy and/or Ozempic, Plaintiff suffered grievous bodily injuries and consequent economic and other losses, as referenced above. As a consequence of Defendants' misconduct, Plaintiff's physicians lacked adequate warnings and other appropriate facts that were misrepresented or omitted from the information (if any) that Defendants provided to physicians for Wegovy and/or Ozempic. Plaintiff suffered injury of a personal and pecuniary nature, including pain and suffering, medical expenses, lost income and disability, and punitive damages.

COUNT III: NEGLIGENCE – DESIGN DEFECT

274. Plaintiff incorporates by reference each allegation set forth in preceding paragraphs as if fully stated herein.

275. Defendants are liable to Plaintiff for the injuries and damages sustained due to Defendants' negligent design and/or formulation of Wegovy and/or Ozempic.

276. At all relevant times to this lawsuit, Defendants owed a duty to consumers including Plaintiff and his health care providers, to assess, manage, and communicate the risks, dangers, and adverse effects of Wegovy and/or Ozempic. Defendants' duties included, but were not limited to, carefully and properly designing, testing, studying, and manufacturing Wegovy and/or Ozempic.

277. Defendants negligently and carelessly breached the above-described duties to Plaintiff by, among other acts and omissions, negligently and carelessly:

(a) Failing to use ordinary care in designing, testing, and manufacturing Wegovy and/or Ozempic;

(b) Failing to design Wegovy and/or Ozempic as to properly minimize the adverse effects to the gastrointestinal and immune system;

(c) Failing to counteract in the design the known adverse effects on the gastrointestinal and immune system;

(d) Designing a product where the benefits were greatly outweighed by the risks malnutrition, cyclical vomiting, gastroparesis, gastroenteritis, intestinal obstruction/blockage, ileus, DVT and associated pulmonary embolism, gallbladder problems necessitating surgery, intraoperative aspiration and death;

(e) Designing a product without taking into consideration the proper dosage that could avoid malnutrition, cyclical vomiting, gastroparesis, gastroenteritis, intestinal obstruction/blockage, ileus, DVT and associated pulmonary embolism, gallbladder problems necessitating surgery, intraoperative aspiration and death;

(f) Wegovy Ozempic was defective in design or formulation in that, when it left the hands of the manufacturers and/or suppliers and/or distributors, the foreseeable risks exceeded the benefits associated with the design or formulation.

278. At all reasonable times, given their lack of efficacy and increased safety risks, Wegovy and/or Ozempic did not meet the reasonable expectations of an ordinary consumer, particularly the Plaintiff, or in the alternative, his medical providers.

279. Wegovy and/or Ozempic was defective in design or formulation in that, when it left the hands of the manufacturers and/or suppliers and/or distributors, it was unreasonably dangerous, more dangerous than an ordinary consumer would expect, and more dangerous than other similar drugs.

280. Despite Defendants' knowledge of the foreseeable risks and unreasonably dangerous nature of Wegovy and/or Ozempic at all times relevant, Defendants designed and brought the products to market and continued to market the drugs when there were safer alternatives available, including but not limited to alternate dosing, reduced exposure, among others.

281. As a result of Defendants' negligent and reckless design, Plaintiff sustained severe and ongoing injuries.

282. As a direct and proximate result of one or more of the above-stated negligent acts by Defendants, Plaintiff suffered grievous bodily injuries and consequent economic and other losses, including pain and suffering, loss of a normal life, medical expenses, lost income and disability, and punitive damages.

COUNT IV: NEGLIGENT MISREPRESENTATION

283. Plaintiff incorporates by reference each allegation set forth in preceding paragraphs as if fully stated herein.

284. At all relevant times, Defendants negligently provided Plaintiff, Plaintiff's healthcare providers, the general medical community, and the public with false, fraudulent, and/or incorrect information and omitted or failed to disclose material information concerning Wegovy and/or Ozempic, including, but not limited to, misrepresentations and marketing regarding the safety and known risks of Wegovy and/or Ozempic.

285. At all relevant times, Defendants negligently provided Plaintiff, Plaintiff's healthcare providers, the general medical community, and the public with false, fraudulent, and/or incorrect information and omitted or failed to disclose material information concerning Wegovy and/or Ozempic, including, but not limited to, misrepresentations and marketing regarding the long term effects of Ozempic and/or Wegovy, including, but not limited to the fact weight lost will be regained upon cessation of the drug.

286. The information distributed by Defendants to the public, the medical community, Plaintiff and his healthcare providers, including advertising campaigns, labeling materials, print advertisements, commercial media, and marketing was false and misleading and contained omissions and concealment of truth about the dangers of Wegovy and/or Ozempic.

287. Defendants' conduct had the capacity to deceive and/or purpose in making these misrepresentations was to deceive and defraud the public and the medical community, including Plaintiff and Plaintiff's health care providers; to falsely assure them of the quality of Wegovy

and/or Ozempic and induce the public and medical community, including Plaintiff and Plaintiff's healthcare providers to request, recommend, purchase, and prescribe Wegovy and/or Ozempic.

288. Defendants had a duty to accurately and truthfully represent and market to the medical and healthcare community, medical pharmaceutical manufacturers, Plaintiff, Plaintiff's healthcare providers and the public, the known risks of Wegovy and/or Ozempic, including its propensity to cause malnutrition, cyclical vomiting, gastroparesis, gastroenteritis, intestinal obstruction/blockage, ileus, DVT and associated pulmonary embolism, gallbladder problems necessitating surgery, esophageal injury, bowel injury, intraoperative aspiration, and death.

289. Defendants made continued omissions and affirmative false statements in the Wegovy and/or Ozempic labeling, including promoting it as safe and effective while failing to warn of its propensity to cause malnutrition, cyclical vomiting, and gastroparesis, gastroenteritis, intestinal obstruction/blockage, ileus, DVT and associated pulmonary embolism, gallbladder problems necessitating surgery, esophageal injury, bowel injury, intraoperative aspiration, and death.

290. Defendants made additional misrepresentations and affirmative false statements beyond the product labeling by representing Wegovy and/or Ozempic as a safe and effective treatment for diabetes and weight-loss with only minimal risks.

291. Defendants misrepresented and overstated the benefits of Wegovy and/or Ozempic to Plaintiff, Plaintiff's treaters, and the medical community without properly advising of the known risks to patients.

292. Defendants made the misrepresentations alleged herein with the intent to induce consumers, like Plaintiff, to take their weight-loss products.

293. In reliance upon the false, deceptive, and negligent misrepresentations and omissions and marketing made by Defendants, Plaintiff and Plaintiff's healthcare providers were induced to, and did use and prescribe Wegovy, and relied upon the affirmative misrepresentations and/or negligent omissions in doing so.

294. As a direct and proximate result of the foregoing negligent misrepresentations and marketing and conduct with capacity to deceive and/or intention to deceive, Plaintiff suffered serious and ongoing injuries.

295. As a direct and proximate result of the foregoing misrepresentations, marketing, and deceitful intentions, Plaintiff requires and/or will require more healthcare and services and did incur medical, health, incidental, and related expenses.

296. Defendants knew or should have known that Plaintiff, Plaintiff's healthcare providers, and the general medical community did not have the ability to determine the true material facts which were intentionally and/or negligently concealed and misrepresented by Defendants.

297. Plaintiff and his healthcare providers would not have used or prescribed Wegovy had the true facts not been concealed by Defendants.

298. Defendants had sole access to many of the material facts concerning the defective nature of Wegovy and/or Ozempic and its propensity to cause serious and dangerous side effects.

299. At the time Plaintiff was prescribed and administered Wegovy, Plaintiff and Plaintiff's healthcare providers were unaware of Defendants' negligent misrepresentations and omissions.

300. Defendants failed to exercise ordinary care in making representations concerning Wegovy and/or Ozempic while they were involved in their manufacture, design, sale, testing, quality assurance, quality control, promotion, marketing, labeling, and distribution in interstate commerce, because Defendants negligently misrepresented Wegovy and/or Ozempic's high risk of unreasonable and dangerous adverse side effects.

301. Plaintiff and Plaintiff's healthcare providers reasonably relied upon the misrepresentations and omissions made by Defendants, where the concealed and misrepresented facts were critical to understanding the true and full dangers inherent in the use of the Wegovy and/or Ozempic.

302. Plaintiff and Plaintiff's healthcare providers' reliance on the foregoing misrepresentations and omissions was the direct and proximate cause of Plaintiff's injuries.

COUNT V: STRICT LIABILITY – FAILURE TO WARN

303. Plaintiff incorporates by reference each allegation set forth in preceding paragraphs as if fully stated herein.

304. Ozempic and/or Wegovy are products within the meaning of Kentucky products liability law.

305. Defendants advertised and promoted Ozempic and/or Wegovy for the purpose of weight loss and diabetes control.

306. Defendants knew or had reason to know of facts establishing that Ozempic and/or Wegovy posed a significant risk of malnutrition, cyclical vomiting, gastroparesis, gastroenteritis, intestinal obstruction/blockage, ileus, DVT and associated pulmonary embolism, gallbladder problems necessitating surgery, intraoperative aspiration and death, and deliberately proceeded to act, or failed to act, in conscience disregard of, or indifference, to that risk.

307. At all times relevant hereto, the defective nature of Ozempic and/or Wegovy was known to Defendants, or reasonably and scientifically knowable to them, through appropriate research and testing by known methods, at the time they distributed, supplied, or sold their respective products, and not known to ordinary physicians who would be expected to prescribe the drug to their patients.

308. Defendants nonetheless failed to provide Plaintiff Angela Hall and her prescribing physicians with adequate warnings due to the following:

- d. Failing to properly and adequately warn and instruct Plaintiff and Plaintiff's treating physicians that Wegovy and/or Ozempic was designed and/or manufactured in a

way that it could cause injuries and damages, including lasting and permanent gastrointestinal injuries;

- e. Failing to timely disclose to Plaintiff and Plaintiff's treating physicians the risks of increased risk of severe gastrointestinal events (e.g., gastroparesis, gastroenteritis, intestinal blockage, ileus, bowel or esophageal injury, cyclical vomiting, and malnutrition), DVT, intraoperative aspiration, gallbladder problems necessitating surgery, and/or death, as well as the need to permanently stay on the drug or the weight will be regained;
- f. Failing to timely warn Plaintiff and Plaintiff's treating physicians that a detailed lab work and patient history should be obtained before starting Ozempic and/or Wegovy.

309. At all relevant times, the labels for Wegovy and/or Ozempic were inadequate because they did not warn and/or adequately warn of all possible adverse side effects associated with the use of Wegovy and/or Ozempic, including the increased risk of severe gastrointestinal events (e.g., gastroparesis, gastroenteritis, intestinal blockage, ileus, bowel or esophageal injury, cyclical vomiting, and malnutrition), DVT, intraoperative aspiration, gallbladder problems necessitating surgery, and/or death, as well as the need to permanently stay on the drug or the weight will be regained.

310. The labels for Wegovy and/or Ozempic were inadequate because they did not contain adequate instructions for use such that a physician and patient could make an informed prescribing decision, adequately monitor the patient while using, and mitigate potential harms from the use of Wegovy and/or Ozempic.

311. At all relevant times, the labels for Wegovy and/or Ozempic were inadequate because they did not warn and/or adequately warn that Wegovy and/or Ozempic had not been sufficiently and/or adequately tested for safety risks, including severe gastrointestinal events (e.g., gastroparesis, gastroenteritis, intestinal blockage, ileus, bowel or esophageal injury,

cyclical vomiting, and malnutrition), as well as DVT, gallbladder problems necessitating surgery, intraoperative aspiration, and/or death.

312. The labels for Wegovy and/or Ozempic were inadequate because they did not warn and/or adequately warn of all possible adverse side effects concerning the failure and/or malfunction of Wegovy and/or Ozempic.

313. The labels for Wegovy and/or Ozempic were inadequate because they did not warn and/or adequately warn of the severity and duration of such adverse effects, as the warnings given did not accurately reflect the symptoms, or severity of the side effects.

314. At all relevant times, communications made by Defendants to Plaintiff and Plaintiff's prescribing physician(s) were inadequate because Defendants failed to warn and/or adequately warn of all possible adverse side effects associated with the use of Wegovy and/or Ozempic, including the increased risk of severe gastrointestinal events (e.g., gastroparesis, gastroenteritis, intestinal blockage, ileus, bowel/esophageal injury, cyclical vomiting, and malnutrition), DVT, gallbladder problems necessitating surgery, intraoperative aspiration, and/or death.

315. At all relevant times, communications made by Defendants to Plaintiff and Plaintiff's prescribing physician(s) were inadequate because Defendants failed to warn and/or adequately warn that Wegovy and/or Ozempic had not been sufficiently and/or adequately tested for safety risks, including severe gastrointestinal events (e.g., gastroparesis and gastroenteritis, intestinal blockage, bowel/esophageal injury, cyclical vomiting, and malnutrition), DVT, gallbladder problems necessitating surgery, intraoperative aspiration, and/or death.

316. Defendants' failure to warn of the above was the proximate cause of Plaintiff's injuries, harm, and economic loss, from which Plaintiff continues to suffer.

317. Defendants' failure to warn of the significant risks of Wegovy and/or Ozempic use prevented Plaintiff and Plaintiff's treating physicians from conducting a proper assessment of the risks and benefits of using Wegovy and/or Ozempic.

318. Had Plaintiff and/or Plaintiff's treating physicians been properly warned of the significant risks of Wegovy and/or Ozempic, they would not have elected to begin and/or continue Wegovy therapy.

319. Reasonable, safer alternative treatments were available to Plaintiff and/or Plaintiff's treating physicians had they been warned of these significant risks.

320. Defendants are therefore strictly liable in tort to Plaintiff pursuant to Kentucky law.

321. As a result of Defendants' failure to warn of the significant risks associated with Wegovy and/or Ozempic, Plaintiff suffered grievous bodily injuries and consequent economic and other losses, as referenced above. As a consequence of Defendants' misconduct, Plaintiff's physicians lacked adequate warnings and other appropriate facts that were misrepresented or omitted from the information (if any) that Defendants provided to physicians for Wegovy and/or Ozempic. Plaintiff suffered injury of a personal and pecuniary nature, including pain and suffering, medical expenses, lost income and disability, and punitive damages.

COUNT VI: STRICT LIABILITY – DESIGN DEFECT

322. Plaintiff incorporates by reference each allegation set forth in preceding paragraphs as if fully stated herein.

323. Ozempic and/or Wegovy are products within the meaning of Kentucky products liability law.

324. Ozempic and/or Wegovy were, at all relevant times, sold and/or distributed by Defendants in a defective condition unreasonably dangerous to users and/or consumers, including Plaintiff Angela Hall, as the risks of Ozempic and/or Wegovy exceeded the benefits.

325. Defendants were, at all relevant times, engaged in the business of selling Ozempic and/or Wegovy.

326. Ozempic and/or Wegovy was expected to reach, and did reach, users and/or consumers, including Plaintiff Angela Hall, without substantial change in the defective and unreasonably dangerous condition in which it was sold or distributed.

327. At all relevant times, safer alternative products and treatments were available to Plaintiff Angela Hall and her treatment providers.

328. Defendants are therefore strictly liable in tort to Plaintiff pursuant to Kentucky law.

329. As a result of Defendants' defective design, Plaintiff suffered grievous bodily injuries and consequent economic and other losses, as referenced above. Plaintiff suffered injury of a personal and pecuniary nature, including pain and suffering, medical expenses, lost income and disability, and punitive damages.

COUNT VII: VIOLATION OF KENTUCKY CONSUMER PROTECTION ACT

330. Plaintiff incorporates by reference each allegation set forth in preceding paragraphs as if fully stated herein.

331. Defendants are liable to Plaintiff pursuant to the Kentucky Consumer Protection Act ("KCPA"). Defendants financed, assisted, supported and participated in the promotion and use of Wegovy and/or Ozempic in order to create a demand for the drug.

332. Defendants deliberately and/or negligently misrepresented the safety of Wegovy and/or Ozempic and concealed the risks attendant to use of the drugs. Through their misrepresentations, Defendants' conduct had the tendency or capacity to deceive, and affected the decisions of consumer and their health care providers to purchase, prescribe and use Wegovy and/or Ozempic, and to exclude the options of not using a drug product for treatment.

333. All Defendants, while engaged in the conduct and practices identified above, committed one or more violations of the KCPA by the use of false and misleading

misrepresentations and/or omissions of material facts and violations related to unfair or deceptive acts or practices, including, but not limited to, the following:

- a. Causing likelihood of confusion or of misunderstanding as to the source, sponsorship, approval, or certification of Wegovy and/or Ozempic;
- b. Representing that Wegovy and/or Ozempic had sponsorship, approval, characteristics, ingredients, uses, benefits or quantities that they do not have;
- c. Representing that Defendants' authors, key opinion leaders, consultants, and speakers did not have a sponsorship, approval, status, affiliation or connection that they did have;
- d. Representing that Wegovy and/or Ozempic were of a particular standard, quality, or grade;
- e. Engaging in other fraudulent or deceptive conduct which created likelihood of confusion or of misunderstanding, as alleged in this Complaint.

334. Defendants' representations were made for the benefit of subsequent purchasers including Plaintiff, the subsequent purchaser here.

335. Plaintiff, while using the product in the usual and customary manner as it was intended to be used, has suffered significant and permanent injuries and damages, including but not limited to physical injury, past and future medical expenses, past and future physical and mental pain and suffering, and will continue to suffer all such damages in the future as a direct and proximate result of Defendants' statements in the advertising and promotional activities to Plaintiff and Plaintiff's medical providers, as described above.

336. Defendants' conduct was committed with knowing, reckless, conscious, wanton, willful, and deliberate disregard for the value of human life and the rights and safety of consumers, including Plaintiff, thereby entitling Plaintiff to punitive and exemplary damages so as to punish and deter similar conduct in the future.

DEMAND FOR JURY TRIAL

337. Plaintiff demands a trial by jury on all the triable issues within this pleading.

PRAYER FOR RELIEF

WHEREFORE, Plaintiff incorporates by reference each preceding and succeeding paragraph as though set forth fully at length herein, and prays for judgment in her favor and against Defendants awarding the following:

338. A monetary award, sufficient to compensate Plaintiff for the following categories of damages:

- a. actual or compensatory damages in such amount to be determined at trial and as provided by applicable law;
- b. actual and treble damages in such amount to be determined by this Court and as provided by law;
- c. exemplary and punitive damages sufficient to punish and deter Defendants and others from future wrongful practices;
- d. pre-judgment and post-judgment interest;
- e. reasonable attorneys' fees as provided by law;
- f. costs including court costs, and other litigation expenses; and
- g. any other relief the Court may deem just and proper.

Dated: 04/26/2024

Respectfully Submitted,

/s/ Jennifer A. Moore

Jennifer A. Moore, Esq.

Attorney I.D. No. 87437

MOORE LAW GROUP, PLLC

1473 South 4th Street

Louisville, KY 40208

T : (502) 717-4080

F : (502) 717-4086

jennifer@moorelawgroup.com

/s/ Noah C. Lauricella

Noah C. Lauricella, Esq.

nlauricella@goldenberglaw.com

GOLDENBERG LAURICELLA, PLLC

800 LaSalle Ave. – Suite 2150
Minneapolis, MN 55402
MN ID No. 397896

T: (612) 333-4662

F: (612) 367-8107

Counsel for Plaintiff